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Abstract
The World Health Organization (WHO) estimates that the total healthcare spending
in the U.S. is around 18% of its GDP for the year 2011. Even with such a high per-
capita expenditure, the quality of healthcare in U.S. lags behind as compared to the
healthcare in other industrialized countries. This inefficient state of the U.S. healthcare
system is attributed to the current Fee-for-service (FFS) model. Under the FFS model,
healthcare providers (doctors, hospitals) receive payments for every hospital visit or
service rendered. The lack of coordination between the service providers and patient
outcomes, leads to an increase in the costs associated with the healthcare management,
as healthcare providers often recommend expensive treatments. Several legislations have
been approved in the recent past to improve the overall U.S. healthcare management
while simultaneously reducing the associated costs.
The HITECH Act, proposes to spend close to $30 billion dollars on creating a nation-
wide repository of electronic Health Records (EHRs). Such a repository would consist
of patient attributes such as demographics, laboratories test results, vital information
and diagnosis codes. It is hoped that this EHR repository will be a platform to improve
care coordination between service providers and patients healthcare outcomes, reduce
health disparities thereby improving the overall healthcare management system. Data
collected and stored in the EHR (HITECH) and the need to improve care efficiency
and outcome (ACT) would help to improve the current state of U.S. healthcare system.
Data mining techniques in conjunction with EHRs can be used to develop novel clin-
ical decision making tools, to analyze the prevalence and incidence of diseases and to
evaluate the efficacy of existing clinical and surgical interventions.
In this thesis we focus on two key aspects of EHR data, i.e. temporality and cau-
sation. This becomes more important considering that the temporal nature of EHRs
data has not been fully exploited. Further, increasing amounts of clinical evidence sug-
gest that temporal nature is important for the development of clinical decision making
tools and techniques. Secondly, several research articles hint at the the presence of anti-
quated clinical guidelines which are still in practice. In this dissertation, we first describe
EHR along with the following terminologies : temporality, causation and heterogeneity.
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Building on this, we then describe methodologies for extracting non-causal patterns in
the absence of longitudinal data. Further, we describe methods to extract non-causal
patterns in the presence of longitudinal data. We describe such methodologies in the
context of Type-2 Diabetes Mellitus (T2DM). Furthermore, we describe techniques to
extract simple and complex causal patterns from longitudinal data in the context of
sepsis and T2DM. Finally, we conclude this dissertation, by providing a summary of
our work along with future directions.
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Chapter 1
Introduction
1.1 Introduction
The World Health Organization (WHO) estimates that the total healthcare spending in
the U.S. is around 18% of its GDP for the year 2011. This represents a steady increase
over the last few decades. Even with such a high per-capita expenditure, the quality
of healthcare in U.S. lags behind as compared to the healthcare in other industrialized
countries. This is corroborated by the fact that U.S. as compared to the other developed
countries has relatively low life expectancy and high in-fact mortality rates.
The U.S. healthcare system is inefficient and wasteful. This can be attributed to
the current Fee-for-service (FFS) model. Under the FFS model, healthcare providers(
doctors, hospitals) receive payments for every hospital visit or service rendered. Hence,
the focus is more on the services rendered to a patient and not on service outcomes.
This lack of coordination between the service providers and patient outcomes, leads
to an increase in the costs associated with the healthcare management, as healthcare
providers often recommend expensive treatments.
Several legislations have been approved in the recent past to improve the overall
U.S. healthcare management while simultaneously reducing the associated costs. These
legislations aim to move from the FFS model towards the Accountable Care Organiza-
tion (ACO) model. Under the ACO model, healthcare provider payments are closely
tied with patient outcomes. In other words, healthcare providers are only paid if there
1
2is any improvement in patient health. Along with the ACO act, The Health Informa-
tion Technology for Economic and Clinical Health (HITECH) Act is another legislation
which aims to improve the overall healthcare management.
Under the HITECH Act, close to $30 billion dollars will be spent on creating a na-
tionwide repository of electronic Health Records (EHRs). Such a repository [1] would
consist of patient attributes such as demographics, laboratories test results, vital infor-
mation and diagnosis codes. Further such information about patient health attributes
will be collected over time. Storing patient healthcare records would enable better doc-
umentation of existing treatments and medical interventions. It is hoped that this EHR
repository will be a platform to improve care coordination between service providers and
patients healthcare outcomes, reduce health disparities thereby improving the overall
healthcare management system. Further such a repository would lay the foundation for
Evidence based Medicine.
Evidence based medicine is a mechanism to improve efficiency as required by the
Accountable Care Act (ACA). Evidence based medicine is a medical practice which aims
to bolster decision making by utilizing evidences from past conducted research for future
patient healthcare recommendations and prescriptions. Such practices hypothesize that
medical decision making, clinical guidelines should be based on best evidences as ob-
served from research and not from an individual clinician’s belief. EHR data could then
be used to validate existing clinical guidelines as data related to medical prescriptions
and recommendations along with the patient’s health outcome over time is present in
EHR. Further, EHRs could also be used for the development of novel clinical guideline
and medical treatments.
The guidelines can be increasingly tailored to the patients to further reduce ineffec-
tive treatment and reduce waste, thereby providing the platform for the development
of Precision Medicine. Precision medicine aims at the development and recommenda-
tion of customized medical treatments, clinical services and products. In such a model,
patients are divided into subpopulations based on their genetic make-up or existing
medical state. Different treatments are then prescribed for these subpopulations aim-
ing to cure the same disease/outcome. An example could be a prescription of a drug
which might lead to healthcare improvement in one population whereas an adverse side-
effect in another sub-population. Hence, the drug would only be recommended for the
3subpopulation for which it has a beneficial effect.
Data collected and stored in the EHR (HITECH) and the need to improve care effi-
ciency and outcome (ACT) would help to improve the current state of U.S. healthcare
system. Evidence based medicine as the clinical framework and Clinical Decision Sup-
port (CDS) as the tool to manage and apply the accumulated knowledge, the time is
ripe to apply data mining towards knowledgable discovery. Data mining techniques in
conjunction with EHRs can be used to develop novel clinical decision making tools, to
analyze the prevalence and incidence of diseases and to evaluate the efficacy of existing
clinical and surgical interventions.
1.2 Scope
In this thesis, we aim to develop methods for extracting knowledge from EHR data.
In particular, we would be using structured EHR datasets for analyzing our techniques
and methodologies. Further, data obtained from parsing clinical notes using Natural
Language Parsing (NLP) tools and techniques, human genetics data (bioinformatics)
and medical imaging are beyond the scope of this thesis. Extracting knowledge from
EHR data is challenging because of the following two reasons.
Firstly, Electronic Health Records (EHRs) is a rich source of longitudinal and time-
series information consisting of patient demographic attributes, laboratories test results,
vital information and diagnosis codes over time [2]. Traditional data mining techniques
exist to analyze longitudinal datasets. However, there is still a need for the development
of sophisticated techniques to analyze irregular time-series datasets [3, 4]. The need for
such techniques becomes more relevant considering that temporal EHR data helps us
to monitor the progression of patient’s health from one medical state to a state of
associated complications.
Secondly, major clinical research studies in the past have often focussed on associ-
ation [5] thereby neglecting causation. In other words, studies have often analyzed the
co-occurrence of symptoms, interventions and outcomes. However, the availability of
longitudinal EHR data provides an opportunity to estimate the efficacy of clinical and
surgical interventions for various outcomes of interest [6, 7, 8, 9].
4This becomes more important considering our observations based on our recent sur-
vey literature. We observed that the temporal nature of EHRs data has not been fully
exploited. Further, increasing amounts of clinical evidence suggest that temporal nature
is important for the development of clinical decision making tools and techniques. Sec-
ondly, several research articles hint at the the presence of antiquated clinical guidelines
which are still in practice. To overcome the aforementioned shortcomings associated
with existing healthcare management,
In this thesis we focus on two key aspects of EHR data, i.e. temporality and causa-
tion. We would be describing these terminologies in greater detail in the next Section.
The overall structure of the thesis is as follows : In Section 2 we describe EHR along
with the following terminologies : temporality, causation and heterogeneity. Building on
this, in Section 3, we describe methodologies for extracting non-causal patterns in the
absence of longitudinal data. In Section 4, we describe methods to extract non-causal
patterns in the presence of longitudinal data. In Section 5, we describe techniques to
extract simple causal patterns from longitudinal data. In Section 6, we describe method-
ologies to extract complex causal patterns from longitudinal data. Finally, we conclude
the thesis in Section 7, by providing a summary of our work along with future directions.
Figure 1 2.2 provides a succinct representation of the layout of Chapters 3,4,5 and 6.
Row labels indicate whether longitudinal data has been utilized in the development of
the proposed techniques. Column labels indicate whether the methodologies are based
on association or causation. All techniques proposed in this thesis are heterogeneity
aware. Moreover, inferring causal inference in the absence of longitudinal data is not
practical and hence would not be focussed upon.
5Figure 1.1: Thesis Succinct Representation
Chapter 2
Background
In this chapter, we will provide a brief description about EHRs data and its constituent
data elements. Further we would also provide a brief discussion about the various
terminologies we would be using in the following subsequent chapters i.e. causation,
temporality and heterogeneity.
2.1 Electronic Health Records Data
Electronic Health Records consists of patient information such as demographics, labo-
ratories test results, vitals information and diagnosis codes. Such information is usually
collected when patients visits a healthcare provider. Data collected through such visits
provide a mechanism to understand the disease incidence, prevalence and underlying
disease mechanisms. Data elements such as demographics attributes, laboratories test
results, diagnosis codes are usually stored in a databases. Information such as vitals
signature are usually stored in flow-sheets which is a semi-structured data storage for-
mat. Clinical Notes are stored as paper records and hence require sophisticated NLP
techniques to parse and extract information. Now we would be describing the data
elements in greater detail :
• Demographics Attributes: Such data elements consist of patient information
such as age, gender, ethnicity, marital status, medical insurance provider and
others. Such information is usually collected and stored when patients visits the
healthcare provider for the first time. This information is usually static in nature.
6
7This attribute is highly heterogenous in nature. For example, gender, ethnicity
are categorical attributes and age is a real-integer valued attribute.
• Laboratories Test Results: These elements are usually collected and stored
based on a clinician’s recommendation. Examples of such elements include read-
ings for glucose, gFR, bilorubin etc. These data elements usually take continuous
values.
• Vital Signs: They are usually collected whenever a patient visits a healthcare
provider. Examples of such data elements include temperature, blood pressure,
body weight, BMI etc. They also take continuous values.
• Diagnosis Codes: These data elements are usually stored when a patient is
diagnosed with any disease. For example, a pre-defined code of 252.0 is usually
assigned to a patient’s health record if the patient is diagnosed with Type-2 Dia-
betes Mellitus.
• Clinical Notes:Such elements usually contain information typically recommended
by a clinician . Examples include lifestyle recommendations, food recommenda-
tions and information about drug or alcohol consumption.
• Other data elements include information related to radiology reports, patient’s
genetic make-up and proteomics data of the patient. Such data elements are not
collected and stored for common hospital visits.
2.1.1 Data Challenges
EHR datasets are prone to numerous challenges arising due to the nature of how such
datasets are stored and collected. Examples of challenges associated with EHR datasets
are censoring, missing data, irregular time-serious, class-imbalance problems, hetero-
geneity and biases. Now, we will discuss these challenges in greater detail.
• Censoring: This refers to the problem when information about a patient is only
partially available. For example, consider the scenario where in a patient registers
in a study , which started in 2012 and continued until 2016. Post some follow-ups
8(2012-2014) the patient drops our of the study. Now there is no way to ascertain
the medical state of the patient in 2015 and 2016. Further, there is no way to
establish whether the study had a beneficial or detrimental effect on the patient.
This kind of data is known as censored data. Censoring can take places in three
ways i.e. right censored data, left censored data and interval censored data.
• Missing data: Missing data in EHRs arises due to numerous reasons. Firstly,
missing data can arise due to fragmentation : a scenario when multiple health-
care providers only contain limited or partial information about a patients health
status. Secondly, it can arise due to different and upcoming standards of storing
EHR information as there might be a correct mapping algorithm from old to new
standard. Thirdly, data can also be missing as a lot of information related to
patient’s health status is entered into clinical notes. Such information can only be
partially extracted using NLP tools and techniques.
• Irregular Timer-Series: Comparing to other data sources such as those ob-
tained in manufacturing settings or in climate sciences, EHR data often comprises
of irregular time series elements. This arises as patients only visit healthcare
providers when there an appropriate need arises. This leads to the occurrence of
irregular spacing between consecutive observation readings. The challenge associ-
ated with such techniques further worsens as traditional data-mining techniques
cannot handle irregular time-series datasets.
• Class-Imbalance: Considering the prevalence of diseases associated with the
human body, some diseases are widely prevalent and some are not. This causes
class imbalance issues when a particular disease of interest has not enough cases
as compared to the controls in any chosen data cohort.
• Heterogeneity: EHRs are very heterogenous data sets considering that some
attributes such as diagnosis codes are binary in nature, demographics attributes
are usually categorical in nature and laboratories test results are continuous in
nature. Another source of heterogeneity arises from the fact that a patient can
progress to the same outcome (e.g. mortality) via varying disease progression
paths. Further, the complexity arises as the probability of progression to the
9outcomes is different along these paths.
• Biases: EHR datasets are often subjected to multiple biases and confounding
effects. Such biases arise when data cohorts do not fully represent the general
population characteristics. For example, an average age of 80 years in a data
cohort does not represent the average age of the general population. Biases can
also subjected to the way the cohort is chosen, the outcomes are designed and the
geographical location where the study was conducted.
2.1.2 Data Opportunities
There are several opportunities associated with mining EHRs datasets. Examples of
such opportunities include understanding disease progression, risk prediction, detecting
adverse events, clinical guideline recommendations, phenotyping and estimating the
effect of interventions. Now, we will describe the various opportunities in greater detail.
• Understanding Disease Progression: This refers to the problem of analyzing
the progression of patient from one state of health to another state of health (asso-
ciated complications). The aim of such analysis is to estimate the prevalence and
incidence of disease across populations. Further, such analysis also provide a plat-
form to understand how disease differ across geographical locations, ethnical and
genetic make-up, across age groups and management of disease across healthcare
providers.
• Risk Prediction This refers to the problem of estimating the probabilities of a
patient’s current risk or progression to any disease of interest. Clinical Decision
Support models aim to assess such risk are usually developed using sophisticated
data mining and machine learning techniques. Examples of such risk prediction
models include Framingham score, Charlson score, etc.
• Detecting Adverse Events This refers to the problem of detecting adverse
events associated with medical or surgical interventions. As EHRs consist of
patient information collected across years, it is often feasible to estimate where
any medical interventions lead to short term or long term adverse events.
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• Clinical Guideline Recommendations These are the clinical protocols usu-
ally followed on a patient during a patient’s inpatient or outpatient visits. For
example, as per American Diabetes Association (ADA) guideline, it is often rec-
ommended that a patient visits a healthcare provider every 6 months to monitor
his/her hemoglobin a1c readings. As EHRs collects information related to clinical
guidelines, it serves as a platform to identify antiquated medical guidelines and
development of novel ones.
• Phenotyping Algorithms Such algorithms are hand crafted or machine learned
rules for identifying whether a patient is diagnosed with any disease. For example,
two consecutive hemoglobin a1c readings (6 months apart) greater than 6.5 clas-
sifies a patient to be diabetic. EHRs can be used to validate existing phenotyping
algorithms or development of novel ones.
• Estimating the Effect of Interventions This refers to the process of estimat-
ing the effect of medical or surgical interventions. As EHRs consists of patient
longitudinal data spread across years, it is often possible to estimate the effect of
interventions in short and long term.
2.2 Thesis Overview
Central to this thesis are the concepts of causation, temporal patterns and heterogeneity.
Now we would be discussing them in greater detail.
2.2.1 Causal Patterns
Causal patterns are patterns that consist of two or more random variables as denoted
by X and Y respectively, such that X causes Y. Our goal is then to estimate the effect
of X on Y. In Fig 2.1, we demonstrate a simple causal pattern which only consist of two
such random variables.
In Fig 2.2, we demonstrate a slightly complex causal pattern which consist of random
variables X,Y and another random variable Z. Z is also referred to as a confounding
random variable. Any estimation obtained, of the effect of random variable X on random
variable Y, without incorporating the effect of random variable Z will be biased in nature.
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Figure 2.1: Causal Structure
Figure 2.2: Causal Pattern with a Confounder
In Fig 2.3, we demonstrate a complex causal pattern which consist of random vari-
ables X,Y and other random variables denoted by U, V, Z and O respectively. In
Chapter 5 and Chapter 6, we would be discussing ways to estimate the effect of X on
Y while simultaneously incorporating the effect of other random variables in detail.
12
Figure 2.3: Causal Pattern with a Confounder and Other Variables
2.2.2 Temporal Information
EHRs are inherently temporal in nature as information about patients health state
is often collected and stored over time. Collecting such information is very vital to
accurately analyze the medical state of the patient because of numerous reasons. Firstly,
collecting such information provides a mechanism to analyze the temporal progression
(laboratories test results or vitals information or diseases) in patients health over time.
Secondly, collecting such information and then analyzing them becomes more relevant
as exposures over time matter (e.g. consistently low body temperature during surgery
are usually associated with increased risk of postoperative complications). Thirdly,
sequence in which events happen are usually predictive of certain outcomes as events
close to the outcome are more important than events which occurred in the distant past.
2.2.3 Heterogeneity
EHRs consist of information collected of highly heterogenous disease mechanisms. These
records provide a platform to explore diseases, which has multiple progression paths to
various events of interest (e.g. mortality). For example, In Figure 2.4, we describe
the progression of a patient from one state of health to another state of health (e.g.
mortality). In our example, we consider three disease of interest i.e. Hypertension,
13
Hyperlipidemia and T2DM and one outcome event i.e. mortality. As observed, even
though the outcome is same (i.e. mortality), the risk estimated by the progression paths
are vastly different.
Figure 2.4: Progression and Risk Assessment of Co-morbid Conditions in Type 2 Dia-
betes Mellitus (T2DM)
Chapter 3
Non-Causal, Non-Temporal
Pattern Mining
3.1 Introduction
In this chapter, we would discuss techniques, which aim to extract non-causal patterns
in the absence of longitudinal data. illustrated in Figure 3.1. Such patterns are widely
used to develop risk estimation indices and computing the probability of progression
from one state of health to another state of health. In this chapter we will illustrate
such patterns in the context of T2DM.
Figure 3.1: Chapter 3 Description
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3.2 Clinical Motivation
Diabetes mellitus (DM) affects 11.3% (25.6 million) of Americans age 20 or older and
is the seventh leading cause of death in the United States [10]. There is considerable
research on risk factors to predict and manage diabetic outcomes [10]. Without ap-
propriate management of diabetes, patients are at risk for secondary diseases in almost
every body system at later time points. Evidence based practice (EBP) guidelines for
management and prevention of diabetic complications synthesize the latest scientific ev-
idence. While EBP guidelines have been shown to improve care, they neither consider
the patient's trajectory nor the sequence of events that lead up to the patient's current
conditions. In this work, we show that such information is invaluable; a patient's risk
of developing further complications depends on their trajectory thus far.
Simple disease models describing a single typical diabetes trajectory as a sequence of
successively worsening conditions exist [11]. However, these models were aimed more
at patient education than at a physiologically accurate description of the evolution of
the underlying disease pathology. Such simple models obviously cannot form the basis
of evidence based guidelines.
In heterogeneous diseases, analyzing the data on a per-subpopulation basis has been
shown to elucidate more interesting patterns than analyzing the entire population [12].
In this chapter, we hypothesize, with abundant supporting evidence [13], that diabetes
and the underlying metabolic syndrome follows multiple trajectories. We aim to develop
a methodology that is capable of elucidating scientifically accurate diabetes trajectories
retrospectively from the extensive clinical data repository of a large Midwestern health
system. Specifically, we study a diabetic population and track changes to their health
over time in terms of diabetes-related comorbidities as documented in the electronic
health record (EHR).
Diabetes, its severity and the ensuing complications can be described most accurately
through a large number of correlated EHR data elements, including associated diag-
noses, laboratory results and vitals. The relationships among these data elements,
known as multicollinearity, render efforts to track patients' conditions across time
fraught with data overfitting issues. To contain the collinearity problem we summa-
rize the patients' condition into a single dimension (a single score), which we term the
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Diabetes Mellitus Complication Index (DMCI).
The development of severity indices from EHRs builds on a rich history. Even in the
context of DM, several risk scores for diabetes from EHRs have been developed [14].
Most risk score models focus on predicting the risk of diabetes rather than the risk
of the associated complications. Two risk scores have specifically focused on diabetes
complications [15, 16] to predict outcomes; however their diabetes complication indices
were limited to the use of complications based on International Classification of Dis-
eases (ICD) codes alone [17] or asking patients if they were ever informed that they
had DM complications [13]. In a diabetic population like ours, good predictors of the
complications do not necessarily coincide with good predictors of diabetes given that
the metabolic syndromes in our patients have already evolved past diabetes. The in-
clusion of additional variables, such as lab results and vital signs may provide useful
information for early prediction of complications. This necessitates the development of
a new diabetes complication index to be used in our effort to study patient trajectories.
In this chapter we make the following novel contributions. First, we develop DMCI
which summarizes a patient's health in terms of post-diabetic complications into a sin-
gle score. Second, through the use of this score, we track a patient's health and show
that distinct trajectories in diabetes can be identified, demonstrating the need and lay-
ing the foundation for future clinical EBP guidelines that take trajectories into account.
3.3 Background
The novel DMCI was developed using Cox proportional hazards survival modeling tech-
niques. Each of the 7 complications (CKD, CVD, CHF, PVD, IHD, Diabetic Foot, Oph-
thalmic) were modeled through a separate Cox regression model using patients who did
not already present with the complication at baseline. Cox Proportional Hazard Models
[18] are survival models which estimate the hazard λj(t) for patient j at time t based on
covariates Zj and a baseline hazard λo(t). The hazard function has the form as shown
in equation 1.
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λj(t/Zj) = λo(t)exp(Zjβ) . . . . . . . . . . . . . . . (1)
The coefficient vector β is estimated through maximizing the partial likelihood. The
partial likelihood can be maximized using the Newton-Raphson algorithm [19]. The par-
tial likelihood [19] has the form as shown in equation 2.
L(β) =pii:Ci=1θi
∑
j:Yj≥Yiθj . . . . . . . . . . . . . . . (2)
θj has the form exp(Zβ) and Ci is an indication function. Ci is 1 if the event oc-
curred and Ci = 0 if the event was censored. The baseline hazard is common to all
patients. Besides the complications (except for the one we are modeling) age, gender,
obesity, hypertension and hyperlipidemia diagnosis, laboratory test results and vitals,
were included as covariates. Backwards elimination [20] was employed for variable se-
lection.
Each of the 7 regression models (one for each complication) provided an estimate of the
coefficients, which can be interpreted as the relative risk of developing the complication
in question. For example, the first regression model estimates the risk of a patient
developing CHF. Similarly the second regression model estimates the risk of patient
developing IHD. In order to compute a patient’s risk for developing diabetes induced
complications, we compute a weighted average of patient’s risk from the six regression
models. Ophthalmic conditions are no longer considered as they have insufficient pa-
tient coverage (less than 100 patients). Patient’s risk from individual regression model
was computed using equation 3.
rij = Zi ∗ βj . . . . . . . . . . . . . . . (3)
where rij denotes the ith patient risk for the jth complication, Zi represents the co-
variates for the ith patient and βj are the coefficients estimated for the jth complication.
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Using this information, the ith patient’s risk (Ri) for any diabetes induced complication
is then computed using equation 4.
Ri =
6∑
j=1
wj ∗ rij . . . . . . . . . . . . . . . (4)
This risk Ri is the risk of a patient developing diabetes related complications. We
named this risk DMCI. The DMCI score is the weighted sum of the linear prediction
from the six regression models. Concordance probability estimates [21] are used to de-
termine the performance of the corresponding regression models. They are also used
to weight the individual regression models. Table 1 represents weights assigned to each
model, with the respective complication as the outcome.
Complication Model Weight
CHF 0.787
IHD 0.569
CVD 0.694
PVD 0.688
CKD 0.758
FOOT 0.712
Table 3.1: Weights For Individual Regression Model
Therefore, the DMCI score can be thought of as approximately 6 times the relative
risk a patient faces in developing a complication (any diabetic complication).
3.4 Methods
Using the DMCI score, the health status trajectory of every patient from 2009 onwards
was calculated. Since individual patient trajectories might be susceptible to noise and
outliers, we decided to group patients and their trajectories (time stamped sequence of
DMCI scores) by complications. First, we considered a single complication at a time,
creating seven categories: patients presenting with CKD, CVD, etc. at baseline. A
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patient presenting with multiple complications falls into all applicable categories. Next,
we considered pairs of complications: e.g. one possible category could consist of patients
with IHD and diabetic foot problems.
For every category (sub-population of patients), the shape of the DMCI score trajectory
was determined through segmented linear regression with 3 knots. One can think about
these regression models as a straight line with one elbow ( at xˆ). These trajectories can
be expressed in the form below,
If ifx< xˆ then y = a*x + b else If ifx≥ xˆ then y = c*x + d
where in a,b,c,d  R.
Residual sum of squares (RSS) was used as the objective function to obtain the
coefficients of the segmented linear regression and the location of the elbow point. RSS
has the form in equation 5
RSS =
n∑
i=1
(yi − yˆi)2 . . . . . . . . . . . . . . . (5)
In equation 5, yi is the risk at ith time stamp and yˆi is the corresponding risk com-
puted using segmented linear regression.
3.5 Data and Study Design
After Institutional Review Board (IRB) approval, a de-identified data set was obtained
from a Midwest University's clinical data repository (CDR). The CDR contains over 2
million patients from a single Midwest health system that has 8 hospitals and 40 clinics.
Data elements included various EHRs attributes, such as demographic information (age,
gender), vital signs: systolic blood pressure (SBP), diastolic blood pressure (DBP),
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pulse, and body mass index (BMI); and laboratory test results: glomerular filtration
rate (GFR), hemoglobin A1c, low-density lipoprotein cholesterol (LDL), high-density
lipoprotein cholesterol (HDL), triglycerides and total cholesterol. Further ICD-9 codes
related to both Type 1 and Type 2 DM, and their accompanied complications such
as ischemic heart disease (IHD), cerebrovascular disease (CVD), chronic kidney disease
(CKD), congestive heart failure (CHF), peripheral vascular disease (PVD), Diabetic
Foot, and Opthalmic complications were used in this study.
For our study, we used Jan. 1, 2009 as a baseline. The study cohort consists
of patients with type 1 or type 2 DM at baseline, identified in billing transactions.
Patients were included if they had at least two A1c results at least 6 months apart after
baseline. Patients with no laboratory results or vitals before 2009 were excluded on
the basis that they show no indication of receiving primary care at the health system.
The final cohort consists of 13,360 patients. Patients' initial DMCI was determined
at baseline, and their health (in terms of the DMCI score) was followed until last the
follow-up. The mean time for follow-up was 1568 with a standard deviation of 263 days.
3.6 Results
Table 3.2 provides the count of patients in various cohorts. Table 3.3 provides the count
for various populations with comorbidities.
Comorbidity Count Comorbidity Count
IHD 4398 CHF 741
CVD 986 PVD 662
CKD 742 Foot 267
Table 3.2: Patient Counts for Single DM Comorbidity
Comorbidity Count Comorbidity Count
IHD, CVD 457 IHD, PVD 379
IHD, CKD 361 IHD, Foot 662
IHD, CHF 478
Table 3.3: Patient Counts for DM Comorbidities
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Figure 3.2 presents the DMCI trajectory for varying subpopulations. The horizontal
axis denotes time since baseline in days and the vertical axis corresponds to the DMCI
score. Each curve in the graph represents a subpopulation defined by a single com-
plication. For example, the bottommost curve corresponds to patients presenting with
CHF at baseline. Their average risk of developing a complication (other than CHF,
which they already have) is 4.4 at baseline, It increases steadily for approximately 550
days, at which point it reaches 4.7 and then it becomes flat (stops increasing materially
going forward). As observed from the graph, the average risk associated with patients
diagnosed with CKD is comparatively higher than that of patients diagnosed with CHF.
Figure 3.2 shows that (i) subpopulations defined by various complications at baseline
have a different average risk at baseline. This information is readily incorporated into
existing indices and guidelines. The figure also shows that (ii) these patients have differ-
ent patterns of risk moving forward. For example, the risk of developing a complication
increases sharply for CHF patients for 550 days and then becomes flat. In contrast, the
risk of IHD increases steadily (but at a lower rate) throughout the observation period;
and CKD (topmost curve) increases at a much lower rate.
Complication Min-Risk Risk-25 Risk-50 Risk-75 Max-Risk
IHD -6.02 1.86 3.92 5.98 22.68
CHF -5.17 1.98 3.86 5.91 12.55
PVD -5.23 2.07 3.90 6.20 14.37
CKD -5.62 1.77 3.94 5.94 14.71
CVD -6.72 2.16 4.00 6.04 14.37
Diabetic Foot -4.64 2.08 3.95 6.08 14.37
Table 3.4: Distribution of Scores for Different Subgroups
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Figure 3.2: Health status trajectory for varying subpopulations
Figure 3.3: Shape of the individual quartiles for patients diagnosed with diabetic foot
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Figure 3.4: Shape of the individual quartiles for patients diagnosed with various com-
plications
Figure 3.2 presents the average risk for each population. To illustrate the distribu-
tion of the risk, in Table 3.3, we provide the interquartile range of the DMCI score in
each subpopulation. Using the information from table 1, the risk trajectories of patients
belonging to the top 25 in their respective subgroups were analyzed. Figure 3.2 presents
the average behavior for the highest-risk quartile.
In order to investigate whether the shape of the health-risk trajectory for each quartile
within a subgroup is similar, the patterns for each quartile for multiple subpopulations
were explored. In Figure 3.2, the shape of the individual quartiles for patients diagnosed
with diabetic foot is depicted. The figure shows that having a different risk at baseline
only tells a part of the story. These patients not only have different risks, but they also
exhibit different progression patterns: their DMCI curves have different shapes.
Figure 3.3, depicts the trajectories of patients with IHD and an additional complica-
tion. The results suggest that even in a subpopulation defined by a single complication,
significant heterogeneity exists, as evidenced by differing shapes of the trajectory curves.
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3.7 Discussion
The purpose of this chapter was to model patients' progression towards diabetes com-
plications through the use of a novel index, DMCI, derived from EHR data. The DMCI
was used to stage the patients' health in terms of diabetic complications. Results
clearly demonstrated the existence of multiple trajectories in diabetes thereby confirm-
ing the complex heterogeneity of the disease. Specifically, we divided patients into
multiple (potentially overlapping) subpopulations based on their baseline complications
and confirmed that patients with different baseline complications have different risks
of developing additional complications. Second, we have also shown that these patient
subpopulations differ not only in their risk but also in the temporal behavior of their
risk: patients in certain subpopulations ‘accrue ’risk at a higher rate initially and at a
slower rate later, while the DMCI score in patients in other subpopulations increases at
a steady rate throughout the follow-up period. Third, we have also demonstrated that
the trajectories differ even within the same patient subpopulation. Patients presenting
with additional complications (e.g. a second complication on top of IHD) have differ-
ent risks and different trajectories. Finally, we have also shown that when we stratify
patients within the same subpopulation by their baseline risk, they exhibit different
trajectories. This can naturally be a consequence of these patients suffering from addi-
tional complications explaining their increased relative baseline risk.
These findings support a conclusion in a previous study that patient subgroups vary by
level of severity. Dey et al. [12] used a national convenience sample of 581 Medicare-
certified HHC agencies' EHRs for 270,634 patients to understand which patients are
likely to improve in their mobility and found that mobility status at admission was
the single strongest predictor of mobility improvement [12]. However, very different
patterns were apparent when conducting the analysis within the level of severity for
mobility at admission.
An interesting finding in our study is that patients with diabetic foot problems have the
highest severity at base line, and more so when combined with IHD. This finding may
be associated with the strict relationship between glycemic control and microvascular
complications. Foot problems are associated both with nerve and vascular damage,
creating a risk for infections. Uncontrolled glucose further exacerbates the potential for
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severe infections and potential amputations. Patients with diabetic foot complications
are likely to continue having an increasing risk for additional problems, as foot prob-
lems are a leading cause of hospital admission, amputation, and mortality in diabetes
patients [16].
Through our previous work [11] in investigating diabetic subpopulations and their risk
of mortality, we have already gained an appreciation of the immense heterogeneity of
diabetes and the metabolic syndrome. Studying trajectories expands this heterogeneity
along a new dimension. While the preliminary work presented in this study merely
offers a glimpse at the complexity of diabetes and its complications, it demonstrates the
value of trajectories in understanding patient progression and possibly prognosis. Fur-
ther research in this direction will undoubtedly lead to improvements in EBP guidelines
by taking trajectories into account.
Limitations of this study include the secondary use of EHR data and its associated
challenges. The data in this study represent care provided in a single health system; the
study needs replication in additional health settings and under different clinical condi-
tions. The DMCI score was developed from EHR data retrospectively and independent
validation would be beneficial.
Chapter 4
Non-Causal Temporal Pattern
Mining
4.1 Introduction
In this chapter, we would discussing techniques to extract and explore non-causal pat-
terns in the presence of longitudinal data as illustrated in Figure 4.1. Such patterns are
widely used to analyze the progression of patients from one state of health to another
state of associated complications. Further, such analysis forms the basis for personalized
and tailored health recommendations. In this chapter we will illustrate such patterns
in the context of T2DM.
Figure 4.1: Chapter 4 Description
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4.2 Clinical Motivation
The use of large repositories of Electronic Health Records (EHR) data for assessing the
risk of adverse outcomes, such as mortality or the development of new complications,
is experiencing a rapid growth in popularity. The most common style of analysis for
this purpose is based on longitudinal retrospective design, where patients are aligned
on a particular point in time (e.g. enrollment into the study), called a baseline, their
state of health at baseline is characterized by elements present in EHR data (baseline
characteristics) and they are followed until last follow-up, at which point they suffer the
adverse outcome in questions or are simply lost to follow-up (are censored).
Such studies have enjoyed great success. Strong epidemiological evidence has been
discovered, which ultimately influenced health care policy. However, the acceptance
and incorporation of these methods into clinical decision support systems is slow. The
design underlying this methodology, where patients’ risk is solely based on baseline
characteristics, is incompatible with clinical practice. Providers constantly reevaluate
patients’ risks and adjust treatment accordingly. When the patient information shows
no clear sign of improvement or deterioration, a common approach is to wait and see. As
time progresses and the patient’s condition further deteriorates, the outcome becomes
more apparent and an appropriate intervention can be administered. When the patient’s
health has deteriorated to the final stages, the outcome can become obvious and also
inevitable: there may be no time for a successful intervention. Knowing not the only
the risk but also the expected timing of adverse events is important, allowing the care
provider to have time to intervene. In this study, we look at a large diabetic population
and aim to mimic the clinical process. We assess the patients’ risk at every encounter,
taking not only the prior conditions but also their sequence into account.
Our working hypothesis is that patients’ health deteriorates following a (small or
large) number of non-random mechanisms. These different mechanisms may affect or-
gans or health indicators (blood sugar, lipid levels, blood pressure) differently, leading
to different sequences of diagnoses. Therefore, the order in which the diagnoses appear
in a patient’s record can be suggestive of the underlying disease mechanism, allowing
us to provide the patient a better prognosis.
Central to this idea is the concept of a trajectory. Formally, a trajectory is a sequence,
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a partially ordered set of conditions, through which patients commonly progress from a
healthy state towards some outcome. We present a method for extracting trajectories,
placing patients onto trajectories and assessing their risk of mortality based on the
trajectories (potentially multiple trajectories) they follow and the extent to which they
have progressed along each trajectory.
Our second key contribution is the introduction of the forensic-style analysis. In
forensic investigation (of say an accident), investigators start from the outcome (acci-
dent) and trace events backwards in time. Factors that contributed to the accident
tend to be most apparent closest to the time of the accident. In a similar vein, in our
forensic-style analysis, we align patients on their outcome (death or censoring) and trace
their conditions backwards over time.
The proposed forensics-style analysis offers several benefits. First, it directly answers
our clinical question of time-to-death, as time in the model represents time-to-death, as
opposed to time-since-enrollment in a typical study.
The second benefit concerns time-dependent covariates. As a patient’s condition
evolves (deteriorates), he develops new conditions, which were naturally not present at
baseline. The predictors of the patient change. Traditional Cox models handle this by
describing the patient with multiple records: every time the patient’s state changes (a
new condition is developed), a new record is added describing the new state along with
the time when the change took place and the record became valid.
Suppose a patient develops disease A 2 years after entering the study, then condition
B 5 years later (7 years into the study) and dies 4 years later (last follow-up is 11 years
after enrollment). This patient would be described with two records: one having A as
the sole covariate and valid time of 2yrs-7yrs; and a second record having both A and
B as covariates and a valid time of 7yrs-11yrs, ending in death. If A is almost always
followed by B when the patient dies, then A will appear to have no risk; all the risk is
assigned to B. To better estimate the risk of A, we could assign the adverse outcome
to both records (as opposed to correctly assigning it only to the second one), but then
the patient appears to die twice at two different times, namely after 7 and 11 years,
respectively. The resultant increase in the baseline hazard at 7 years is incorrect. If
we measured time backwards from the last follow-up, both records would indicate the
29
correct time of death, allowing us to correctly measure the risk of disease A.
We evaluated our method on the EHR data of a large health care system in the
Midwestern United States in the context of the metabolic syndrome including type-II
diabetes, its co-morbidities and complications.
In this chapter, we make the following contributions:
1. We propose modeling patients’ risk of adverse outcome based on the trajectories
they follow and the extent to which they have progressed along these trajectories;
thus allowing us to take the sequence of events into account.
2. We introduce the forensic-style analysis, which aligns patients on last follow-up
and measures time backwards. Measuring time backwards allows us to estimate
the time-to-event more directly.
3. We modified the Cox proportional hazard model, using forensic-style analysis,
to better model time-dependent covariates. Specifically, we modified how the
outcome is designated, allowing the fitting algorithm to better estimate the risk
of diseases in earlier stages of the trajectories.
The proposed method is a general methodology that can be applied to different time-
to-event problems. Given the importance of diabetes and our expertise in diabetes, we
describe and evaluate the method in the context of diabetes and the metabolic syndrome.
The chapter is organized as follows. Section II describes current state of the art
techniques used to handle time-to-event data. Section III-A introduces terminology
associated with trajectories. Section III-B discusses techniques for extracting frequent
trajectories. In Section III-C we present our model and optimization framework. In
Section IV, we discuss our results. Finally, Section V presents our conclusions.
Survival modeling techniques on time-to-event data have been explored widely in
the past. Cox regression [22, 23] is one of the most commonly used survival regression
models. Its formulation, namely its semi-parametric nature, with the mild assumption
of the proportionality of hazards, makes it ideal for many practical applications in fields
such as economics [24], healthcare [25, 26, 27] and recommendation systems [28].
Cox models, as most other regression techniques, are susceptible to overfitting. Stan-
dard regularization techniques, developed for other regression methods, have been ap-
plied to Cox models, as well. Lasso [29] and elastic-net regularized Cox models [30]
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have been developed, and have been further extended by regularizing them with con-
vex combinations of L1 and L2 penalties [31]. We are not aware of regularization for
time-dependent covariate Cox models [32], which would be a straightforward extension.
Chandan et. al [33] proposed an active learning based survival model which uses a
novel model discriminative gradient based sampling scheme and observed better sam-
pling rates as compared to other sampling strategies. They also proposed correlation
based regularizers with Cox regression to handle correlated and grouped features which
are commonly seen in many practical problems [34]. Similarly Gopakumar et al. pro-
posed a stabilized sparse Cox model of time-to-events using clinical structures inherent
in Electronic Medical Records. They estimated the feature graph derived from two types
of EMR structures: the temporal structure of disease and intervention recurrences, and
the hierarchical structure of medical knowledge and practices [35]. To handle the high-
dimensionality of high-throughput genomic data, Kuang et al. [36] extended Cox models
by proposing network-based Cox regression model called Net-Cox and applied Net-Cox
for a large-scale survival analysis across multiple ovarian cancer datasets.
Support vector machine [37] models have also been extended to handle censored data
[38, 39, 40, 41]. In such techniques, often the task is converted into a ranking problem
via the concordance index. This in turn is efficiently solved using convex optimization
techniques. Along similar lines, Khosla et al. [42] proposed a margin based censored
regression algorithm which combines margin-based classifiers with censored regression
algorithms to achieve a better concordance index. They used their technique to identify
potential novel risk markers for heart stroke.
Research has also been carried out on extending decision trees to handle censored
data [43]. Ishwaran et al. [44] proposed Random Survival Forests for analyzing right
censored survival data. They analyzed splitting rules for growing survival trees, intro-
duced a new measure of mortality and applied it for patients diagnosed with coronary
artery disease. Neural nets have also been adapted to handle censored data with varying
results [45, 46]. Techniques such as reverse survival [4] have also been explored in the
past wherein they go further back in time.
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4.3 Background
We consider seven diseases in the context of diabetes. These are hyperlipidemia (HL;
high cholesterol), hypertension (HTN; high blood pressure), type-II diabetes mellitus
(DM), chronic kidney disease (CKD), ischemic heart disease (IHD), cerebro-vascular
disease (CVD), and congestive heart failure (CHF). These are chronic diseases; once
the presence of the disease has been confirmed, they remain active. The patient may
have the condition under control (i.e. a patient can have normal laboratory results),
but the disease remains.
4.3.1 Trajectory Terminology
Not all mentions of these diseases in the patient’s record indicate a new diagnosis.
Often, these diagnosis are present for billing purposes, as they complicate treatment.
To determine the precedence of the diseases in the trajectories, we need to focus on
new (incident) diagnoses. The term ‘incident’ refers to the diagnosis creating a new
incidence, as opposed to being a chronic condition in the background that complicates
the treatment of a different disease. To identify incident diagnoses, we need to determine
the status of diseases at any time point.
The disease is confirmed if we have evidence that the patient presents with the
disease; it can be ruled out if we have evidence that the patient does not have the
disease; or the status can be unknown otherwise (when we do not have evidence either
way).
Definition 1 (Disease confirmed) A disease is confirmed at time t and thereafter,
if the patient’s record has a diagnosis code, a prescribed medication or an abnormal lab
result (if applicable) related to the disease.
Definition 2 (Disease ruled out) A disease is ruled out at time t and before, if no
pertinent medication prescription or diagnosis code is present at or before t and a normal
laboratory result is present at t.
Definition 3 (Incident diagnosis) A new disease diagnosis is incident at t if the
disease is ruled out before t and confirmed after t.
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In plain language, a disease diagnosis is new (or an incident diagnosis) if we have
evidence that it is new: it was absent before t and is present at t. For IHD, CVD and
CHF, we do not have laboratory results to rule them out, so we assume that the first
diagnosis of these diseases in our data is an incident diagnosis.
Definition 4 (Background disease) Non-incident diagnosis of a confirmed disease.
A background disease is a confirmed as a preexistent condition or a potentially
preexisting condition that we cannot rule out. If a patient enters the study with (say)
HTN, then HTN is a background disease (confirmed preexisting condition). If the first
appearance of HL (high cholesterol) is a year after enrollment, but the patient does not
have cholesterol measurements before the diagnosis, then HL is background (the patient
may have had HL all along). If, however, we have a normal cholesterol measurement
before the HL diagnosis, then the HL is incident, because we rule it out for (some part
of) the first year.
Definition 5 (Precedence) A disease A precedes disease B, A → B, (or B follows
A) in a patient, if the patient has an incident disease B at time t and A is a background
or incident disease before t.
Since B is an incident disease, we ruled it out before t, while A could not be ruled
out before t, thus A occurred earlier than B.
Definition 6 (Trajectory) A trajectory is a set of diseases, some incident, some back-
ground, with precedence information among them. In other words, a trajectory is a
partially temporally ordered set of diseases.
Example. T = (A,B) → C → D is a trajectory with A and B being background
diseases, whose ordering cannot be determined from our data and C and D are incident
diseases, hence their ordering is known. The precedence information is transitive, so
beside the depicted A → C, B → C and C → D precedence relationships, A → D
and B → D also hold. These diseases are chronic, hence at the time when the patient
develops C, he also has A and B; and at the time he develops D, he also has A, B and
C.
The central idea in our work is to place patients on trajectories, which requires that
we define when a trajectory applies to a patient or matches a patient’s trajectory.
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Definition 7 (Sub-trajectory) A trajectory S is a sub-trajectory of T if the diseases
in S are a subset of the diseases in T and all precedence information in T that relates
to the diseases in S holds true in S.
Example. The trajectory S = B → C is a subtrajectory of T , as it contains a subset
of the diseases B and C and all precedence relationships involving B or C in T , namely
B → C, also holds true in S.
Definition 8 (Prefix trajectory) A trajectory P is a prefix trajectory of T if P is a
subjectory of T and no disease in T precedes any of the diseases in P .
Example. S = (A,B) → C is a prefix trajectory of T as none of the diseases in T
precede the diseases in S. In contrast, B → C is not a prefix of T as there is a disease
A in T that precedes C in T .
Definition 9 (Matching) A trajectory T applies to a patient with trajectory X (or
matches X) iff (i) there exists a prefix P of T that is a subtrajectory of X and (ii) there
exists no disease d in X, such that d is not a part of P but is present in T .
Example. Consider a patient trajectory X = A → B → C → D. The trajectory
T = A → B → E matches X with prefix P = A → B, because the only disease in T
that is not in P (namely E) is not in X. The clinical motivation behind this definition
is that the patient with trajectory X may be following T , just has not progressed to E
yet. (He may also follow other trajectories that explain C and D).
4.3.2 Algorithm for Extracting the Frequent Trajectories
Our goal is enumerate all trajectories that patients frequently follow that end in mor-
tality. Therefore, for trajectory extraction, we only consider patients who died and do
not consider patients who remained alive after last follow-up.
We apply the venerable a-priori algorithm [47] to enumerate all sub-trajectories that
occur in at least 4 patients. With 2814 total deaths, the support of 4 (support fraction
of 4/2814) is the smallest support fraction that does not contain 0 in its 95% confidence
interval. Trajectories that occurred in less than 3 patients can be random as 0 would be
present in the confidence interval. The purpose of this 4-patient threshold was merely
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to establish a minimal reasonable standard for trajectories, it was not to extract an
optimal set of trajectories. The discovered set of trajectories (library trajectories) will
be passed to an optimization algorithm that will select the final trajectories.
In our application , we only have seven diseases thus the number of discovered
trajectories is not a concern. With more diseases, the number of trajectories can grow
exponentially, making the number of discovered trajectories a concern. Several remedies
are available. The number of trajectories can be decreased through numerous heuristics,
including the following:
• increasing the support threshold to correct for simultaneous hypothesis testing,
• increasing the support without any statistical justification,
• mining only maximal subsequences (sub-trajectories),
• mining approximately maximal subsequences (if the support of a trajectory differs
only minimally from the support of one of its sub-trajectory, the sub-trajectory
in question can be discarded), or
• frequent-set summarization techniques [48] can be easily adapted to sub-trajectories.
Heuristics to filter frequent item-sets and sequences have a rich literature and studying
these heuristics is outside the scope for this work. We rely on the feature-selection
facility of our modeling algorithm to select trajectories.
Output. The output of the algorithm is a library (set) of trajectories, which we call
library trajectories that end in mortality and occur frequently in patients who suffered
mortality. Some of these trajectories can be sub-trajectories of each other.
4.4 Methods
Given a potentially large and redundant set of library trajectories, discovered above,
our goal in this section is to a develop a methodology for (i) selecting trajectories and
(ii) to estimate the risk of mortality in patients, who may follow zero, one or more of
the library trajectories.
.1. Data Format.
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The trajectories are transformed into a binary design matrix X. The columns of
X correspond to diseases along the trajectories: each disease along each trajectory is
mapped to its own column. The rows of X correspond to patients during different time
periods, active periods. Therefore, for the ith record, we have the associated trajectory
information xi (ith row in X), the beginning bi and end ei time of the active period, the
patient id pi and the outcome yi. The indicator Ai(t) signals whether record i is active
at time t; it returns 1 for bi ≥ t > ei. Note that in our forensic-style analysis, time is
measured backwards, so bi > ei.
For each patient, the active time periods are defined by changes in the trajectory:
whenever the patient develops a new disease which corresponds to progression along a
trajectory, we add a new record with the appropriate timing information. Therefore each
record represents a new state, where the patient has progressed further (has accumulated
more diseases).
The outcome yi is 1 if the patient pi had an adverse outcome exactly bi time after
the beginning of the record. In contrast to Cox models with varying covariates, the
outcome is 1 for all records of the patient. While it may appear that the patient had
died multiple times, our definition of bi (being measured from death) ensures that these
”multiple” deaths coincide at the right time point. The baseline hazard can compensate
for the multiplicity of deaths.
.2. Model.
The model is a variant of the Cox Proportional Hazards Regression model. Central to
the model is the concept of hazard, which we define analogously to the Cox terminology,
namely, as the instantaneous probability of death in exactly t time from an event.
λ0(t) exp(xiβ) (4.1)
where λ0(t) is a time-dependent baseline hazard that is common across all patients and
the trajectories xi increase the hazard proportionally.
Given our design matrix X described earlier, the expression xiβ expands into
xiβ =
∑
L∈L(bi)
∑
d∈L(bi)
βL,d (4.2)
where L(bi) is the set of library trajectories that apply to the patient pi at time bi,
the diseases d are the diseases confirmed for the patient at or before time bi along the
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trajectory L, and βL,d are the coefficients. The sum
∑
d∈L βL,d is the (log) relative risk
that having reached d along trajectory L confers on the patient. Notice that the (log)
relative risk along a trajectory cumulates in a (log-)additive fashion, indicating that
each events along the trajectory also confers a proportional hazard.
We can estimate the “probability” of death (technically, expected count of deaths)
for patient p at time t as
Λp(t) =
t∑
τ=0
λ0(τ) exp(xiβ), for i : Ai(τ) = 1, pi = p (4.3)
for all records i where the records is active at time τ and describes patient p.
.3. Likelihood.
The likelihood is the probability that for each patient p after developing each disease
d, the outcome happens exactly time t after developing the disease.
∏
i
[
λ0(t) exp(xiβ)∑
j Aj(t)λ0(t) exp(xjβ)
]yi
for i : t = bi, j : bj ≥ t > ej (4.4)
Defining the vector of linear risk score u as u = xβ, the log likelihood becomes
`(u) =
∑
i
yi
ui − log∑
j
Aj(bi) expuj
 (4.5)
.4. Optimization
Our goal with the optimization is (i) select a subset of the library trajectories for
modeling and (ii) estimate their coefficients. We optimize β iteratively through a gra-
dient boosting framework [49], adding a new trajectory in each iteration. Adding a
library trajectory, say L, is equivalent to changing the corresponding set of coefficients
in β, which we denote by βL.
Performing boosting (gradient ascent in u-space), leads to the update
u(k+1) = u(k) + γ
d`
du(k)
, (4.6)
where γ is the learning rate, u(k) is the linear risk score u in the kth iteration and ` is
the log likelihood function.
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In iteration k, we need to find the trajectory that fits d`/du(k) the best. Let ∇`
denote the gradient d`/du(k). We wish to find the trajectory L, with coefficient vector
βL, such that the quantity
minβL (∇`− xLβL)′(∇`− xLβL)
is minimal across all trajectories. The prime sign (’) denotes matrix (vector) transposi-
tion.
Once we find the optimal trajectory along with the optimal βL, we can update the
β vector.
The learning rate γ can be determined through line-search or can also be chosen as
an arbitrary small number.
Stopping criterion. We stop adding trajectories, when the improvement of ` on either
the training or a validation set is less then a pre-defined small positive number ε.
Initialization. We can either start with an empty set of trajectories, or we can provide
a pre-selected set of trajectories resulting from a greedy coverage of the events in the
patient trajectories. For our experiments, we started with an empty set.
Gradient. To derive ∇`, we first separate out a particular component uk from ` and
then derive the partial derivative with respect to uk.
` =
∑
i
{yiui − yi log [Aj(bi) expuj ]}
=
ykuk − yk log
Ak(bk) expuk +∑
j 6=k
Aj(bi) expuj

+
∑
i 6=k
yiui − yi log
Ak(bk) expuk +∑
j
Aj(bi) expuj

∂`
∂uk
= yk − yk Ak(bk) expuk∑
j Aj(bk) expuj
(4.7)
−
∑
i 6=k
yi
Ak(bi) expuk∑
j Aj(bi) expuj
= yk −
∑
i
yi
Ak(bi) expuk∑
j Aj(bi) expuj
(4.8)
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The sum iterates over all records i that began during the active time of record k divided
by the summed risk of records j that started when i was active. Thus the partial
derivative can be restated in a more familiar form
∂`
∂uk
= yk −
ek∑
τ=bk
(∑
i
yi∑
j Aj(τ) expuj
)
expuk, (4.9)
for i : bi = τ.
= yk −
ek∑
τ=bk
λ0(τ) expuk (4.10)
Unlike in the regular Cox models, the gradient is not the residual, only a part of
the residual that the corresponding record is responsible for. For gradient boosting, it
is not required that the gradient coincides with the residual. The form of the partial
derivative, however, suggests a form for the cumulative hazard that parallels the Breslow
estimate [50] in Cox models, which we presented in Eq. 4.3.
4.5 Data and Study Design
Data.
We use the clinical data repository of a large health care system situated in the
Midwestern United States. Based on data availability, we selected 2005 to 2014 as the
study period. We included all adult patients who developed type-II diabetes during
this period. Mortality data from the state death registry was available for 8,000 of
these patients. Our health care system has a large tertiary care arm, thus many of the
patients may receive their primary care (and possibly diabetes care) outside this system
leading to large gaps in the data. To exclude such patients, we required the study
population to have at least 2 Hemoglobin A1c measurements at least 1 year apart. The
final cohort consists of 2,814 cases (patients who died) and almost 2,000 controls (who
were censored).
For these patients, we collected diagnoses, lab values, vitals and medication data.
We use a combination of these data elements to determine whether a patient has each
of the seven diseases at each point in time, as described earlier. Almost all patients had
a history of obesity, so we dropped this variable.
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In Table 4.1, we present our patient population statistics for both the cases and
controls for the purpose of direct comparison. Cases and controls appear to have similar
conditions at baseline, but cases deteriorate more rapidly. The table also shows that we
have laboratory results and diagnoses for almost all patients.
4.6 Results
Our problem is not a traditional computer science problem hence methods to compare
it against are very few, and mostly in biostatistics and epidemiology. We decided to
evaluate our algorithm by showing that all innovations we claim improve the perfor-
mance. We claim three innovations: (i) the use of trajectories, (ii) the forensic-style
design: patients are aligned on the last follow-up and time is measured backwards from
last-follow-up and (iii) designation of the outcome for the records belonging to the same
patient. Accordingly, we will build four models, starting from the simplest model (the
one that is typically used to solve this problem) and successively add our proposed
features to it to isolate the effect of each of our contributions.
(1) Enrollment-Aligned Design. The typical approach to time-to-event problems
is to conduct a retrospective study, where patients are aligned on their enrollment into
the study and are followed until mortality or until they get lost to follow-up (until
censoring). In other words, time in the model denotes time since enrollment measured
in months. The baseline in our case translates into the first appearance of the patient
in the EHR and last follow-up is the time stamp of the last piece of information in the
EHR, or their date of death in the death registry.
The modeling method is Cox proportional hazards model with time-dependent co-
variates [32]. Patients are represented by multiple records, where each record describes
a time-slice of the patients progression between two changes, i.e. the time points when
new diagnoses appeared in the patient’s record. As recommended for this design, only
the last record of the cases (patients who died) is marked with death as an outcome.
Naturally, none of the records of controls indicate a positive outcome. The predictors
in this model are the seven diseases.
This is the simplest and most common model to solve our problem.
(2) Outcome-Aligned Design. The next simplest model aligns patients on outcome,
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which admittedly, is an unusual but reasonable design. Suppose patient i has follow-up
Ti. We select a time T , which is larger than all Ti’s and designate T as the last follow-up
for all patients. Consequently, in this design, we align patients on their last follow-up
(which happens at time T for all patients by design). Their enrollment time into the
study will vary, it will be T − Ti for patient i. This design assumes that the baseline
hazard depends on time from death. This stands in sharp contrast with the assumption
of the Enrollment-Aligned Design, which assumes that the baseline hazard depends on
time from enrollment. Therefore, the Outcome-Aligned Design incorporates exactly one
aspect of the proposed forensic-style analysis: alignment on outcome (i.e. alignment on
the last follow-up).
The modeling algorithm is still Cox proportional hazard model with time-dependent
covariates and the outcome for the patients is still designated in the usual way: only the
last record has positive outcome (death) for the cases. Although we have aligned patients
on last follow-up, naturally, not all of their records end at last follow-up, therefore
designating all records of cases as positive would still appear as if the patients had died
at multiple time points.
(3) Forensic-Style Design. This is the design proposed in this manuscript. Forensic-
Style Design is similar to Outcome-Aligned Design in that patients are aligned on last
follow-up, but it goes beyond by measuring time backwards. Measuring time backwards
allows us to designate all records of cases (patients who died at last follow-up) as positive
and still retain the correct time of death across all records.
Since the likelihood has a different meaning in this design, we use our own fitting
algorithm from Section 4.5. we use seven ”trajectories” each consisting of a single
disease, thus our predictors are the diseases. We will refer to this model as ’fast w/o
traj’ (FAST without trajectories).
(4) Forensic-Style Analysis Via Survival Trajectories (FAST). The experiment
is designed using the Forensic-Style Design, but instead of the seven diseases, we use
trajectories as predictors. This is precisely the proposed methodology.
Evaluation Method
Given the time-to-event outcome, our evaluation metric is survival concordance.
This is a widely used metric for time-to-event data. For any two patients, i and j, i
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having a higher risk of death than j, survival concordance measures the probability that
i dies earlier than j. Patient pairs, for which it is not possible to determine whether the
higher risk patient dies earlier (e.g. he is still alive at last follow-up), are ignored. Ties
(patient pairs with the same risk and same time-to-death) are also ignored. Note that
i and j are different patients: two records of the same patient are not compared.
Survival concordance is similar to the C-statistic (or binary concordance, a.k.a area
under the receiver operator curve) in that a random model, a model where the predicted
risk is independent of the outcome, would give a concordance of .5, a perfect model
would give 1. Survival concordance can also give a concordance value less than .5 if the
estimated risk decreases with increasing actual risk.
To estimate the survival concordance in the presence of multiple records per-patient,
we use 100-iterations of (grouped) bootstrap estimation. Our method is a computation-
ally more efficient version of the robust estimator suggested in [51, Ch 8.2]. Although
bootstrapping can increase the bias slightly as compared to jackknife [52, Ch. 11], but
given the large number of patients (approx. 4,000), we are not overly concerned.
The sampling unit for the bootstrap resampling is a patient: all records of each
patient are either included or excluded. In each bootstrap iteration, we use the out-of-
bag (OOB) samples for testing and the resampled (bootstrapped) data set for training.
30% of the training set is left out for validation. Again, all records of each patient are
either in the training set or in the validation set; we never split them between both.
Boosting achieves regularization through early termination; hence we use the validation
set to determine when to terminate the optimization process. The resultant model is
then evaluated on the OOB sample.
In Figure 4.2, we present the survival concordance of the four models across the 100
bootstrap replications.
Effect of Aligning Patients on Outcome. The ’enrollment’ and ’outcome’ models
use the same fitting algorithm (time-dependent Cox model), the same predictors (the
seven diseases) and only differ in the study design: in the ’enrollment’ model, patients
are aligned on their enrollment into the study, while in the ’outcome’ model, they are
aligned on their last follow-up.
The benefit of aligning patients on last follow-up is clear. In the Enrollment-Aligned
Design, time represents time-since-enrollment, which is not associated with death. On
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Figure 4.2: Concordance of the various designs estimated through bootstrapping.
the other hand, in case of the Outcome-Aligned Design, time is related to the time
of death: time of death happens exactly at the same time point for all patients (by
definition). Aligning patients on their time of death (or censoring) allows for more
accurate description of the so-called risk set : the patients who were under observation
at the time, having the potential for an event. (This is the denominator in the likelihood
function.)
Effect of Outcome Designation. To assess the effect of the outcome designation, we
can compare the ’outcome’ model with the ’fast w/o traj’. Both of these models utilize
a study design that aligns patients on the outcome; the difference between them lies
in measuring time backwards and the outcome designation this change enables. The
beneficial effect of this difference is very significant as observed from the paired t-test
performed between survival concordance values of the two methods (p-value 1e-16).
Our choice of outcome designation was motivated by the following observation.
Given a trajectory a→ b→ c that ends in death, in the typical study design (Enrollment-
Aligned or even Outcome-Aligned), when the patient only has a, or has a and b, his
outcome is still designated as ’alive’. Since death rarely follows a or b without c, this
designation leads the fitting algorithm to believe that a and b are protective. The result
is negative coefficients for these diseases and a survival concordance less than .5 (see
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the ’enrollment’ model).
What is surprising is that this observation holds true even without trajectories. HL
and HTN occur in early stages of the metabolic syndrome and thus death rarely follows
these conditions directly.
Effect of using trajectories. Finally, ’fast w/o trajectories’ and ’fast’ differ only in
the use of trajectories. The use of trajectories is advantageous (p-value 7.5e-6).
When trajectories are not utilized, the model only has seven predictors. Estimating
seven coefficients from 12k records contributed by 5k patients is trivial. On the other
hand, it is suspected that these seven conditions affect the risk of mortality differently
depending on the presence of other conditions.
When trajectories are utilized, the model is very flexible, allowing it to capture
the clinical reality better. Unfortunately flexibility translates into increased model de-
grees of freedom, making the model susceptible to overfitting. The FAST algorithm is
regularized to help it avoid or at least alleviate overfitting.
Comparison to Other Penalized Models. We have considered comparing FAST
with other penalized regression models, however, there are two major obstacles. First,
currently existing penalized regression implementations (most notably glmnet) do not
support time-dependent covariates, rendering any comparison unfair.
Second, our trajectory-based boosting scheme resembles a grouped lasso [53] penalty
(although they are not equivalent). Using penalized regression would allow us to draw
upon the rich set of penalization techniques that have already been developed (e.g.
structured lasso), but, these techniques have not been implemented for Cox models.
Given that are focus is on the three innovations, rather than on studying regularization
in this context, we decided that comparing regularization schemes is out of scope for
this work, and did not implement these regularization schemes for Cox models with
time-dependent covariates.
4.6.1 In-Depth Look at the FAST Results
Above, we have shown that the performance of FAST is substantially and (statistically)
significantly better than any other model we have considered. In this section, we are
going to show some of the resultant models.
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Table 4.2 presents the coefficients of the three models that do not rely on trajectories.
These are coefficients obtained from regular Cox models and thus their interpretation
is as follows. For example, the relative risk of mortality that CHF (congestive heart
failure) confers on a patient is exp(−.24) = .79; a patient with CHF is 21% less likely
to die than the average patient in our cohort. The coefficients of HL and HTN are 0
or NA because these diseases occur in nearly all patients. As a result, their risk is not
reasonably estimable. (’fast w/o traj’ did not select these variables, either.)
The model based on the Enrollment-Aligned Design indicates that CHF is protective
from mortality; and all three of these models suggest that Chronic Kidney Disease
(CKD) and Cerebro-Vascular Disease (CVD) are also protective. Based on clinical
knowledge, these findings are patently wrong. The correct interpretation is that patients
with CKD will most likely die from a different immediate cause and not from CKD itself.
Ergo, these models do not tell us the risk of mortality conferred on the patient by CKD.
FAST Models.
In this section, we turn our attention to the FAST model. To assess the statistical
significance of the coefficients, we ran 500 bootstrap replications, resulting in 500 models,
each potentially using a different set of trajectories.
Most of the 500 models used only one (392 models) or two trajectories (34 models)
and on the other extreme, there were models using 20, 22, and 28 trajectories (one model
each). In Table 4.3, we present the trajectories that appeared in at least 10 models.
The table presents the trajectory, followed by the number of models that utilized this
trajectory in parenthesis. We then present the average coefficients (across the models
that utilized this trajectory) of the diseases along the trajectory and also the empirical
p-value of the coefficient, which is the fraction of bootstrap iterations in which the sign
of the coefficient in question was the opposite of the sign of the mean.
To illustrate the interpretation of these trajectories, consider for example, the last
trajectory: HTN → HL→ DM . (All trajectories end in death so we omit the outcome
from the trajectory description.) Patients along this trajectory first develop hyperten-
sion (high blood pressure; HTN), then hyperlipidemia (high cholesterol; HL), followed
by diabetes (DM) and they die without developing any diabetes complication. The
relative risk of mortality conferred upon the patients by this trajectory (relative to the
entire population) is exp(.09)=1.09 at the stage of HTN, exp(.09+.13)=1.24 by the
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time they progress to HL and exp(.09+.13+.20)=1.52 when they develop diabetes. The
same patients could potentially follow other trajectories, as well, which could increase
or decrease their relative risk.
Let us consider the first trajectory, DM,HL,HTN → CHF , as a different example.
Patients along this trajectory have pre-existent HL, HTN, and DM and develop CHF
afterwards. In this trajectory, the sequence in which the initial HL, HTN and DM
are developed is unknown, a patient who has developed them in any order matches
this trajectory. Since patients can develop them sequentially (others can have them
upon enrollment into the study), we can still estimate the effects of these conditions
individually.
The sixth trajectory, HTN → HL → DM → CHF , is a more specific version of
the above DM,HL,HTN → CHF trajectory, where the ordering of HTN, HL and DM
is fixed. If both trajectories are selected into a model, which is the case in 37 of the
41 models that selected the sixth trajectory, both trajectories apply to the patients, so
the coefficients of the more specific trajectory can be viewed as modifiers to the general
trajectory: in these patients the effects of HTN and HL are less severe but that of DM
is more severe. If such a modification was not necessary, this trajectory would not be
selected. This shows that the same conditions can have different effects depending on
the order in which the diseases were developed.
The models that utilized trajectories were able to give more correct estimates for the
diabetes complications (CVD, CHF, IHD, CKD). Recall that the models that did not
utilize trajectories ended up estimating some of these severe conditions as protective
(Table 4.2); this does not happen with trajectories: the coefficients of the diabetes
complications are always positive, which is consistent with our clinical expectation.
4.7 Discussion
In this manuscript we presented Forensic-style Analysis based on Survival Trajectories
(FAST). FAST makes two key contributions: it places patients onto disease trajectories
to assess their risk of progression to an adverse outcome (mortality in our study) and
it performs a forensic-style analysis, where patients are aligned on their last follow-up
and time is measured backwards. Measuring time backwards allows a third ancillary
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contribution: we can designate the outcome as positive for all records of cases (patients
who ultimately died), potentially leading to better estimates of the effects of diseases
that occur early in the progression.
The typical method for solving this problem comes from the domain of epidemiology
as a combination of study design (longitudinal retrospective: patients are aligned on
enrollment and followed longitudinally) and a modeling algorithm Cox proportional
hazards model with time dependent covariates.
When the patients’ state does not evolve over time, namely they entered the study
with a set of diseases and had the same set of diseases at last follow-up, our method
simplifies to this above typical method and measuring time backwards or forwards,
aligning patients on enrollment or outcome will not make a difference. This is situation
for the vast majority of the studies in existence.
When the patients’ state evolves over time, our proposed method starts to differ.
To isolate the effect of our innovations, we successively enhanced this baseline method
(which we referred to as Enrollment-Aligned Design) by adding our contributions one
at a time. We have thus demonstrated the benefit of aligning patients on outcome when
we believe that time-to-death is important; we demonstrated the benefit of our outcome
designation and we have also isolated the beneficial effect of using trajectories.
We then took a deeper look at our proposed methodology to show that it conforms
with medical knowledge. We have shown that unlike the models that did not utilize
trajectories, the trajectory based model identified diabetes complications as harmful.
The Outcome-Aligned model identified the heart diseases (IHD and CHF) as harmful,
and indeed these diseases often lead to mortality, but only the trajectory based method
identified CKD and CVD as factor that increase the risk of mortality.
Another hypothesis was the models with the traditional outcome designation may
incorrectly designate early risk factors as protective. Many patients entered the study
with HTN and HL causing the design matrix of our study to become near-singular, thus
the coefficients of HTN and HL could not be estimated at all. Some trajectories use one
or the other, thus through the trajectories it because possible to estimate their effect
(but only within a trajectory). Given the high disease burden of our study population,
we cannot expect positive coefficients for all diseases along all trajectories: some pa-
tients with some diseases have below-average risk of death. However, we found some
47
trajectories, e.g. the last two in Table 4.3, which have early diseases and yet have all
positive coefficients.
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Dead Censored
Total Number of Patients 2814 1976
Average Age At First Encounter 63.83 61.83
At Last Encounter 72.41 66.22
Mean Number of Follow-up Years 8.58 4.35
Patient diagnosis history
DM at first encounter 1032 713
by last encounter 2496 1753
HL at first encounter 1630 832
by last encounter 2631 1636
HTN at first encounter 1572 1084
by last encounter 2803 1885
CHF at first encounter 96 78
by last encounter 875 159
IHD at first encounter 206 243
by last encounter 1039 447
CVD at first encounter 80 82
by last encounter 604 152
CKD at first encounter 67 150
by last encounter 1093 343
Male 1383 1062
Female 1431 914
Number of patients with lab results
Blood pressure 2771 1887
a1c 2814 1976
Lipid panel 2666 1553
GFR 2812 1128
Number of patients with abnormal lab results
Blood pressure 2811 1511
a1c 2741 1556
Lipid panel 2535 1243
GFR 450 306
Table 4.1: Demographics Statistics of Patient population
covariate enrollment outcome fast w/o traj
HL – – 0.00
HTN – – 0.00
DM 14.56 16.24 8.21
CKD -0.45 -0.21 -0.07
IHD 0.42 0.05 0.00
CVD -0.28 -0.37 -0.01
CHF -0.24 0.10 0.00
Table 4.2: Coefficients of the non-trajectory based models
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HL HTN DM CKD IHD CVD CHF
DM,HL,HTN → CHF (263)
coefs -0.23 -0.31 0.13 – – – 1.21
p-val 0.04 0.00 0.06 – – – 0.00
DM,HL,HTN → CKD (192)
coefs -0.25 -0.30 0.12 1.09 – – –
p-val 0.03 0.01 0.04 0.00 – – –
DM,HL→ HTN → CKD (41)
coefs -0.10 -0.11 -0.04 0.76 – – –
p-val 0.02 0.02 0.27 0.00 – – –
HL,HTN → DM → CKD (30)
coefs -0.13 -0.05 0.11 0.88 – – –
p-val 0.13 0.43 0.47 0.00 – – –
HTN → DM,HL→ CKD (22)
coefs -0.07 -0.07 0.01 0.83 – – –
p-val 0.18 0.14 0.50 0.00 – – –
HTN → HL→ DM → CHF (16)
coefs -0.05 -0.01 0.15 – – – 0.86
p-val 0.25 0.50 0.25 – – – 0.00
HL,HTN → IHD (16)
coefs -0.03 0.07 – – 0.56 – –
p-val 0.38 0.12 – – 0.00 – –
DM,HL,HTN → IHD (14)
coefs -0.10 -0.15 0.03 – 0.69 – –
p-val 0.36 0.29 0.43 – 0.14 – –
HL→ HTN → CV D → DM (14)
coefs 0.02 0.03 0.13 – – 0.70 –
p-val 0.36 0.18 0.00 – – 0.00 –
HTN → HL→ DM (10)
coefs 0.09 0.13 0.20 – – – –
p-val 0.00 0.00 0.00 – – – –
Table 4.3: Trajectories and their coefficients that were utilized in at least 10 models
Chapter 5
Simple Causal Pattern Mining
5.1 Introduction
In this chapter, we would discussing techniques to extract simple causal patterns in the
presence of longitudinal data as illustrated in Figure 5.1.
Figure 5.1: Chapter 5 Description
By simple causal patterns, we imply those patterns which consists of three groups
of random variables. Group X consists of random variable, whose intervention we wish
to computer, Group Y consists of random variables (i.e. outcome variables). Group Z
consists of random variables which are also known as confounding variables. Figure 5.2
illustrates such patterns.
Such patterns are widely used to estimate the effect of medical or surgical interven-
tions on outcomes of interest. Further, such analysis forms the basis for identification of
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Figure 5.2: Simple Causal Pattern
antiquated guidelines, development of new guidelines and discovery of adverse events.
In this chapter we will illustrate such patterns in the context of T2DM.
5.2 Clinical Motivation
According to the Center for Disease Control and Prevention, the incidence of sepsis or
septicemia has doubled from 2000 through 2008, and hospitalizations have increased by
70% for these diagnoses[54]. In addition, severe sepsis and shock have higher mortality
rates than other sepsis diagnoses, accounting for an estimated mortality between 18%
and 40% [55, 56]. During the first 30 days of hospitalization, mortality can increase to
a range of 10% to 50% [57] depending on the patients risk factors. Patients with severe
sepsis or septic shock are sicker, have longer hospital stays, and are more frequently dis-
charged to other short-term hospital or long-term care institutions than patients with
other conditions.
The use of evidence-based practice (EBP) guidelines, such as the Surviving Sepsis Cam-
paign (SSC) [58], could lead to an earlier diagnosis, and consequently, earlier treatment.
However, these guidelines have not been widely incorporated into clinical practice. The
SSC is a compilation of international recommendations for the management of severe
sepsis and shock [58]. Many of these recommendations are interventions to prevent fur-
ther system deterioration during and after diagnosis. Even when the presence of sepsis
or progression to sepsis is suspected early in the course of treatment, timely implemen-
tation of adequate treatment management and guideline compliance are still a challenge
[59]. Therefore, the effectiveness of the guideline in preventing clinical complications
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for this population is still unclear to clinicians and researchers alike.
The majority of studies have focused on early detection and prevention of sepsis
and little is known about the compliance rate to SSC and the impact of compliance on
the prevention of sepsis-related complications. Further, the measurement of adherence
to individual SSC recommendations rather than the entire SSC is, to our knowledge,
limited [60] . The majority of studies have used traditional randomized control trials
with analytic techniques such as regression modeling to adjust for risk factors known
from previous research [61]. Data-driven methodologies, such as data mining techniques
and machine learning, have the potential to identify new insights from electronic health
records (EHRs) that can strengthen existing EBP guidelines.
The national mandate for all health professionals to implement interoperable EHRs by
2015 provides an opportunity for the reuse of potentially large amounts of EHR data to
address new research questions that explore patterns of patient characteristics, evidence-
based guideline interventions, and improvement in health [62, 63, 64]. Furthermore,
expanding the range of variables documented in EHRs to include team-based assessment
and intervention data can increase our understanding of the compliance with EBP
guidelines and the influence of these guidelines on patient outcomes. In the absence of
such data elements, adherence to guidelines can only be inferred; it cannot be directly
observed.
In this chapter, we present a methodology for using EHR data to estimate the
compliance with the SSC guideline recommendations and also estimate the effect of the
individual recommendations in the guideline on the prevention of in-hospital mortality
and sepsis-related complications in patients with severe sepsis and septic shock.
5.3 Methods
Missing Data: Any observation that took place before the estimated onset of sep-
sis (TimeZero) was considered baseline observation. Simple mean imputation was the
method of choice for imputing missing values. Imputation was necessary for lactate
(7.7%), temperature (3%), and WBC (3%). There was no missing data for the other
variables and for the outcomes of interest. Central venous pressure was not included as
a baseline characteristic due to the high number of missing values (54%).
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Propensity Score Matching : Patients who received an intervention may be in
worse health than patient who did not receive an intervention. For example, patients
whose lactate was measured may have more apparent (and possibly advanced) sepsis
than patients whose lactate was not measured. To compensate for such disparities,
propensity score matching (PSM) was employed. The goal of PSM is to balance the
data set in terms of the covariates between the exposed and unexposed groups. This
is achieved by matching exposed patients with unexposed patients on their propensity
(probability) of receiving the intervention. This ensures that at TimeZero, pairs of
patients, one exposed and one unexposed, is at the same state of health and only differs
in their exposure to the recommendation. PSM is a popular technique for estimating
treatment effects [65, 66].
To compute the propensity of patients to receive treatment, a logistic regression
model was used, where the dependent variable is exposure to the recommendation and
the independent variables are the covariates. The linear prediction (propensity score) of
this model was computed for every patient. A new (matched) population was created
from pairs of exposed and unexposed patients with matching propensity scores. Two
scores match if they differ by no more than a certain caliper (.1 in our study) [67]. The
effect of the recommendation was estimated by comparing the incident fraction among
the exposed and unexposed patients in the matched population.
PSM nested inside Bootstrapping Simulation:In order to incorporate the ef-
fect of additional sources of variability arising due to estimation in the propensity score
model and variability in the propensity score matched sample, 500 bootstrap samples
were drawn from the original sample [68]. In each of these bootstrap iterations, the
propensity score model was estimated using the above caliper matching techniques and
the effect of the recommendation was computed with respect to all outcomes. In recent
years, bootstrap simulation has been widely employed in conjunction with PSM to bet-
ter handle bias and confounding variables17. For each recommendation and outcome,
the 500 bootstrap iterations result in 500 estimates of the effect (of the recommendation
on the outcome), approximating the sampling distribution of the effect.
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5.4 Data and Cohort
Data from the EHR of a health system in the Midwest was transferred to a clinical data
repository (CDR) at the University of Minnesota which is funded through a Clinical
Translational Science Award. After IRB approval, de-identified data for all adult pa-
tients hospitalized between 1/1/09 to 12/31/11 with a severe sepsis or shock diagnosis
was obtained for this study.
The sample included 186 adult patients age 18 years or older with an ICD-9 diagnosis
code of severe sepsis or shock (995.92 and 785.5*) identified from billing data. Since
785.* codes corresponding to shock can capture patients without sepsis, patients without
severe sepsis or septic shock, and patients who did not receive antibiotics were excluded.
These exclusions aimed to capture only those patients who had severe sepsis and septic
shock, and were treated for that clinical condition. The final sample consisted of 177
patients. Variables of Interest
The fifteen predictor variables (baseline characteristics) were collected. These in-
clude socio-demographics and health disparities data: age, gender, race, ethnicity, and
payer (Medicaid represents low income); laboratory results: lactate and white blood
cells count (WBC); vital signs: heart rate (HR), respiratory rate (RR), temperature
(Temp), mean arterial blood pressure (MAP); and diagnoses for respiratory, cardiovas-
cular, cerebrovascular, and kidney-related co-morbid conditions. ICD-9 codes for co-
morbid conditions were selected according to evidence in the literature. Co-morbidities
were aggregated from the patients´ prior problem list to detect preexisting (upon admis-
sion) respiratory, cardiovascular, cerebrovascular, and kidney problems. Each category
was treated as yes/no if any of the ICD-9 codes in that category were present.
The outcomes of interest were in hospital mortality and development of new com-
plications (respiratory, cardiovascular, cerebrovascular, and kidney) during the hospital
encounter. New complications were determined as the presence of ICD-9 codes on the
patients´ billing data that did not exist at the time of the admission.
This chapter aims to analyze compliance with the SSC guideline recommendations
in patients with severe sepsis or septic shock. Therefore, the baseline (”TimeZero”) was
defined as the onset of sepsis and the patients were under observation until discharged.
Unfortunately, the timestamp for the diagnoses is dated back to the time of admission;
55
hence the onset of sepsis needs to be estimated. The onset time for sepsis was defined
as the earliest time during a hospital encounter when the patient meets at least two
of the following six criteria: MAP < 65, HR > 100, RR > 20, temperature < 95or >
100.94,WBC < 4or > 12, andlactate > 2.0. The earliest time when two or more of
these aforementioned conditions were met, a TimeZero flag was added to the time of
first occurrence of that abnormality, and the timing of the SSC compliance commenced.
Guideline Compliance SSC guideline recommendations were translated into a readily
computable set of rules. These rules have conditions related to an observation (e.g. MAP
¡ 65 Hgmm) and an intervention to administer (e.g. give vasopressors) if the patient
meets the condition of the rule. The SSC guideline was transformed into 15 rules, one
for each recommendation in the SSC guideline, and each rule was evaluated for each
patient.
We call the treatment of a patient compliant with a specific recommendation, if the
patient meets the condition of the corresponding rule any time after TimeZero and the
required intervention was administered; the treatment is non-compliant if the patient
meets the condition of the corresponding rule after TimeZero, but the intervention was
not administered (any time after TimeZero); and the recommendation is not applicable
to a treatment if the patient does not meet the condition of the corresponding rule. In
estimating compliance (as a metric) with a specific recommendation, we simply mea-
sure the number of compliant encounters to which the recommendation is applicable.
We also estimate the effect of the recommendation on the outcomes. We call a patient
exposed to a recommendation, if the recommendation is applicable to the patient and
the corresponding intervention was administered to the patient. We call a patient un-
exposed to a recommendation if the recommendation is applicable but was not applied
(the treatment was non-compliant). The incidence fraction in exposed patients with
respect to an outcome is the fraction of patients with the outcome among the exposed
patients. The incidence fraction of the unexposed patients can be defined analogously.
We define the effect of the recommendation on an outcome as the difference in the inci-
dence fractions between the unexposed and exposed patients. The recommendation is
beneficial (protective against an outcome) if the effect is positive, namely, the incidence
faction in the unexposed is higher than the incidence fraction in the unexposed patients.
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5.5 Results
Table 1 shows the baseline characteristics of the study population. Results are reported
as total count for categorical variables, and mean with inter-quartile (25%-75%) range
for continuous variables. As shown in Table 1, the majority of patients were male,
Caucasian, and had Medicaid as the payer. Before the onset of sepsis, Cardiovascular
co-morbidities (56.4%) were common, the mean HR (101.3) was slightly above the nor-
mal, as well as lactate (2.8), and WBC (15.8). The mean length of stay for the sample
was 15 days, ranging from less than 24 hours to 6 months. TimeZero was within the
first 24 hours of admission, and patients at that time were primarily (86.4%) in the
emergency department.
Feature Mean
Total Number of Patients 177
Average Age 61
Gender(Male) 102
Race(Caucasian) 97
Ethnicity(Latino) 11
Payer(Medicaid) 102
White Blood cell 15.8
Lactate 28
Mean blood Pressure 73.9
Temperature 98.4
Heart Rate 101.3
Respiratory Rate 20.6
Cardiovascular 100
Cerebrovascular 66
Respiratory 69
Kidney 62
Table 5.1: Demographics statistics of patient population
Fifteen rules from the SSC recommendations were identified. Figure 5.3 presents a
description of these rules along with the number of patients whose treatment was com-
pliant with the recommendation in question. Y means the treatment of the patient was
compliant, N indicates non-compliant and N/A means the recommendation (rule) was
not applicable or could not be calculated. Using this information, rules LactateFluid,
GlucoseInsulin, MAP, MAPFluids, CVPFluids, Albumin, and Diuretic were removed
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as patient coverage, either in the exposed or unexposed group, was insufficient. Rules
BCulture, Antibiotic, Lactate, BGlucose, Vasopressor, CVP, RespDistress, and Venti-
lator were included.
Figure 5.3: SSC rules for measuring guideline compliances
In Figure 5.4, the difference in the mean rate of progression to complications between
the exposed and unexposed groups is depicted. Since we used bootstrap simulation, for
each rule-complication pair, 500 replications were performed resulting in 500 estimates
for the effect. These estimates are presented as boxplots. The panes (groups of box-
plots) correspond to the complications and the boxes within each pane correspond to
the recommendation (rule). For example, the effect of the Ventilator rule (Recommen-
dation 15: patients in respiratory distress should be put on ventilator) on Death is
shown in the rightmost box (Ventilator) in the bottom-most pane (Death). Since all
effects in the boxplot are above 0, namely the number of observed complications in the
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unexposed group is higher than in the exposed; compliance with the Ventilator rule re-
duces the number of deaths. Therefore, the corresponding recommendation is beneficial
(on mortality). The use of Ventilator was also beneficial in reducing the Respiratory
and Cardiovascular complications. Similarly, checking glucose was found beneficial in
reducing Respiratory and Cardiovascular complications.
To further ensure the validity of the results, we examine the propensity score dis-
tribution in the exposed and unexposed group. As an illustration, Figure 5.5 depicts
the propensity score distribution for a randomly selected bootstrap iteration to measure
the effect of Ventilator on Death. The horizontal axis represents the propensity score,
which is the probability of receiving the interventions, and the vertical axis represents
the density distribution, namely the proportion of patients in each group with a partic-
ular propensity for being put on Ventilator. Figure 2 shows substantial overlap between
the propensity scores in the exposed and unexposed group.
5.6 Conclusion
The overall purpose of this study was to use EHR data to determine compliance to the
Surviving Sepsis Campaign (SSC) guideline and measure its impact on inpatient mor-
tality and sepsis complications in patients with severe sepsis and septic shock. Results
showed that compliance with many of the recommendations was outstanding: MAP was
measured in all patients, and the recommendations related to checking blood culture,
lactate, blood glucose, and respiratory distress were followed in the overwhelming ma-
jority of the patients.
On the other hand, the treatment of a large number of patients was not compliant with
the CVP Fluids recommendation (to perform fluid resuscitation in patients with CVP
below 2). This may be due to a study design artifact, where the rule only considered
interventions initiated after TimeZero (estimated onset of sepsis), while the fluid resus-
citation may have taken place earlier. Alternatively, the apparently poor compliance
could also be explained with issues related to the coding of fluids: during data valida-
tion, we found that the majority of fluids were not coded in the system.
Our study also demonstrates that retrospective EHR data can be used to evaluate the
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effect of compliance with guideline recommendations on outcomes. We found a number
of SSC recommendations that were statistically significantly protective against more
than one complication: Ventilator and BGlucose were protective against Death (not
BGlucose), Respiratory and Cardiovascular.
Other recommendations, BCulture, Antibiotic, Vasopressor, Lactate, CVP, and Re-
spDistress, showed results less consistent with our expectation. For instance, Vasopres-
sor used to treat low MAP, appears to increase cerebrovascular complications. While
this finding is not strictly statistically significant, it may be congruent with the fact
that small brain vessels are very sensitive to changes in blood pressure. Low MAP can
cause oxygen deprivation, and consequently brain damage.
Ventilator, Vasopressor, and BGlucose showed protective effects against Respiratory
complications. The SSC guideline recommends the implementation of ventilator ther-
apy as soon as any change in respiratory status is noticed. This intervention aims to
protect the patient against further system stress, restore hypoxia, help with perfusion
across the main respiratory-cardio vessels, and decrease release of toxins due to respi-
ratory efforts.
Our study is a proof-of-concept study demonstrating that EHR data can be used to
estimate the effect of guideline recommendations. However, for several combinations
of recommendations and outcomes, the effect was not significant. We believe that the
reason is that guidelines represent workflows and the effect of the workflow goes beyond
the effects of the individual guideline recommendations. For example, by considering
the recommendations outside the context of the workflow, we may ignore whether the
intervention addressed the condition that triggered its administration. If low MAP trig-
gered the administration of vasopressors, without considering the workflow, we do not
know whether MAP returned to the normal levels thereafter. Thus we cannot equate
an adverse outcome with the failure of the guideline, it may be the result of the insuffi-
ciency of the intervention. Moving forward, we are going to model the workflows behind
the guidelines and apply the same principles that we developed in this work to estimate
the effect of the entire workflow.
Another limitation of the study concerns timing. For this analysis, guideline compliance
was considered only after TimeZero (the estimated onset), since compliance with SSC
is only necessary in the presence of suspected or confirmed sepsis. There is no reason
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to suspect sepsis before TimeZero. However, some interventions may have started ear-
lier, without respect to sepsis. For example, 100% of the patients in this sample had
antibiotics (potentially preventive antibiotics), but only 99 (55%) patients received it
after TimeZero.
A third limitation is that EHR does not provide date and time for certain ICD-9 diag-
noses. During a hospital stay, all new diagnoses are recorded at the day of admission.
We know whether it was present on admission or not, thus we know whether it is a pre-
existing or new condition, but do not know precisely when the patient developed this
condition during the hospitalization. For this reason, we are unable to detect whether
the SSC guideline was applied before or after a complication occurred, thus we may
underestimate the beneficial effect of some of the recommendations. For example, high
levels of lactate is highly related to hypoxia and pulmonary damage9. If these patients
were checked for lactate after pulmonary distress, we would consider the treatment com-
pliant with the Lactate recommendation, but we would not know that the respiratory
distress was already present at the time of the lactate measurement and we would in-
correctly count it as a complication that the guideline failed to prevent.
This study demonstrated that retrospective EHR data could be used to estimate com-
pliance with individual guideline recommendations in the SSC guideline. Further, EHR
data can be used to estimate the effect of guideline adherence on sepsis-related compli-
cations in patients with severe sepsis and septic shock. We found that most treatment
courses we observed were compliant with many guideline recommendations and were
able to demonstrate these recommendations have significant beneficial (protective) ef-
fect on some outcomes. Since guidelines encapsulate a workflow, which goes beyond
a mere collection of recommendations, further study is needed to prove the beneficial
effect of the entire SSC workflow.
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Figure 5.4: Causal effect estimation for different outcomes across subpopulations
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Figure 5.5: Propensity Score Overlap
Chapter 6
Complex Causal Pattern Mining
6.1 Introduction
In this chapter, we would discussing techniques to extract simple complex patterns in
the presence of longitudinal data as illustrated in Figure 6.1.
Figure 6.1: Chapter 6 Discussion
By complex causal patterns, we imply those patterns which consists of random
variables as denoted in 6.2. These random variables have been discussed in detail in
the later part of this chapter. Such patterns are widely used to estimate the efficacy of
medical and clinical interventions for outcomes of interest. In Chapter 5, we discussed
simple causal patterns wherein only the effect of confounding variables was incorporated
to estimate the effect of random variable X on random variable Y. In this Chapter 6,
we will also incorporate the effect of random variables U,V and O while incorporating
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the effect of X on Y. In this chapter we will illustrate such patterns in the context of
T2DM.
Figure 6.2: Complex Causal Pattern
6.2 Clinical Motivation
Effective management of human health remains a major societal challenge as evidenced
by the rapid growth in the number of patients with multiple chronic conditions. Type-II
Diabetes Mellitus (T2DM), one of those conditions, affects 25.6 million (11.3%) Amer-
icans of age 20 or older and is the seventh leading cause of death in the United States
[10]. Effective treatment of T2DM is frequently complicated by diseases comorbid to
T2DM, such as high blood pressure, high cholesterol, and abdominal obesity. Currently,
these diseases are treated in isolation, which leads to wasteful duplicate treatments and
suboptimal outcomes.
Finding optimal treatment for patients who suffer from multiple associated diseases,
each of which can have multiple available treatments is a complex problem. We could
simply use techniques based on association, but a reasonable algorithm would likely
find that the use of a drug is associated with some unfavorable outcome. This does not
mean that the drug is harmful; in fact in many cases, it simply means that patients who
take the drug are sicker than those who do not and thus they have a higher chance of
the unfavorable outcome. What we really wish to know is whether a treatment causes
an unfavorable outcome, as opposed to being merely associated with it.
The difficulty in quantifying the effect of interventions on outcomes stems from
subtle biases. Suppose we wish to quantify the effect of a cholesterol-lowering agent,
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statin, on diabetes. We could simply compare the proportion of diabetic patients in
the subpopulation that takes statin and the subpopulation that does not and estimate
the effect of statin as the difference between the two proportions. This method would
give the correct answer only if the statin-taking and non-statin-taking patients are
identical in all respects that influence the diabetes outcome. We refer to this situation as
treated and untreated patients being comparable. Unfortunately, statin taking patients
are not comparable to non-statin-taking patients, because they take statin to treat
high cholesterol, which by and in itself increases the risk of diabetes. High cholesterol
confounds the effect of statin. Many different sources of bias exist, confounding is just
one of the many. In this manuscript, we are going to address several different sources
of bias, including confounding.
Two key challenges arise when trying to estimate the effect of multiple interventions
First, is the issue of comparability : to estimate the effect of intervention, we need two
groups of patients who are identical in all relevant aspects except that one group receives
the intervention and the other group does not. For a single intervention, the first group
is typically the sicker patients who still do not get treated and the second group consists
of the healthier patient who get treatment. They are reasonably in the same state of
health. However, when we go from a single intervention to multiple intervention and
try to estimate their joint effect, comparability no longer exists. A patient requiring
multiple simultaneous interventions is so fundamentally different from a patient who
does not need any intervention that they are not comparable.
Analogously, to care providers adjusting drugs one or two at a time rather than
introducing then to the treatment regiment in large sets, we will estimate the effect
of large intervention sets sequentially. Not only does this approach provide more re-
liable estimates it directly helps provide chose the appropriate treatment under many
conditions.
The other key challenge in finding optimal intervention sets for patients with com-
binatorial sets of diseases is the combinatorial search space. Even if we could trivially
extend the methods for quantifying the effect of a single intervention to a set of con-
current interventions, we would have to systematically explore a combinatorially large
search space. The association rule mining framework [69] provides an efficient solution
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for exploring combinatorial search spaces, however, it only detects associative relation-
ships. Our interest is in causal relationships.
In this manuscript, we propose causal rule mining, a framework for transitioning
from association rule mining towards causal inference in subpopulations. Specifically,
given a set of interventions and a set of items to define subpopulations, we wish to find
all subpopulations in which effective intervention combinations exist and in each such
subpopulation, we wish to find all intervention combinations such that dropping any
intervention from this combination will reduce the efficacy of the treatment. We call
these closed intervention sets, which are not to be confused with closed item sets. As a
concrete example, interventions can be drugs, subpopulations can be defined in terms of
their diseases and for each subpopulation (set of diseases), our algorithm would return
effective drug cocktails of an increasing number of constituent drugs. Leaving out any
drug from the cocktail will reduce the efficacy of the treatment.
To address the exploration of the combinatorial search space, we propose a novel
frequency-based anti monotonic pruning strategy enabled by the closed intervention
set concept. The essence of anti-monotonic property is that if a set I of interventions
does not satisfy a criterion, none of its supersets will. The proposed pruning strategy
based on closed intervention sets allows for additional pruning beyond the support based
pruning strategy used by the Apriori algorithm [69].
Underneath our combinatorial exploration algorithm, we utilize the Rubin-Neyman
model of causation [70]. This model sets two conditions for causation: a set X of
interventions causes a change in Y iff X happens before Y and Y would be different
had X not occurred. The unobservable outcome of what would happen had a treated
patient not received treatment is a potential outcome and needs to be estimated. We
present and compare five methods for estimating these potential outcomes and describe
the biases these methods can correct.
Typically the ground truth for the effect of drugs is not known. In order to assess the
quality of the estimates, we conduct a simulation study utilizing five different synthetic
data sets that introduce a new source of bias. We will evaluate the effect of the bias
on the five proposed methods underscoring the statements with rigorous proofs when
possible.
We also evaluate our work on a real clinical data set from the Mayo Clinic. We have
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data for over 52,000 patients with 11 years of follow-up time. Our outcome of interest is
5-year incidence of T2DM and we wish to extract patterns of interventions for patients
suffering from combinations of common co-morbidities of T2DM. First, we evaluate our
methodology in terms of the computational cost, demonstrating the effectiveness of the
pruning methodologies. Next, we evaluate the patterns qualitatively, using patterns
involving statins. We show that our methodology extracted patterns that allow us to
explain the controversial patterns surrounding statin [71].
Contributions. (1) We propose a novel framework for extracting causal rules consisting
of multiple interventions with multiple outcomes in subpopulations of interest. (2) We
introduce the concept of closed intervention sets to extend the concept of quantifying
the effect of a single intervention to a set of concurrent interventions thus sidestepping
the patient comparability problem. Closed intervention sets also allow for a pruning
strategy that is strictly more efficient than the traditional pruning strategy used by the
Apriori algorithm [69]. (3) We compare five methods of estimating causal effect from
observational data that are applicable to our problem and rigorously evaluate them on
synthetic data and mathematically prove (when possible) why they work.
6.3 Background
Consider a set X of items, which are single-term predicates evaluating to ‘true’ or
‘false’. For example, {age > 55} can be an item. A k-itemset is a set of k items,
evaluated as the conjunction (logical ’and’) of its constituent items. Consider a dataset
D = { d1, d2.....dn }, which consists of n observations. Each observation, denoted by
Dj is a set of items. An itemset X={x1, x2, . . . , xk} (X ⊂ I) supports an observation
Dj if all items in X evaluate to ‘true’ in the observation. The support of X is the
fraction of the observations in D that support X. An itemset is frequent if its support
exceeds a pre-defined minimum support threshold.
A association rule is a logical implication of form X ⇒ Y , where X and Y are
disjoint itemsets. The support of a rule is (XY ) and the confidence of the rule is
(Y |X).
Given an intervention itemset X and an outcome item Y , such that X and Y
are disjoint, a causal rule is an implication of form XY , suggesting that X causes a
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change in Y . Let the itemset S define a subpopulation, consisting of all observations
that support S. This subpopulation consists of all observations for which all items in S
evaluate to ‘true’. The causal rule XY |S implies that the intervention X has causal
effect on Y in the subpopulation defined by S. The quantity of interest is the causal
effect, which is the change in Y in the subpopulation S caused by X. We will formally
define the metric used to quantify the causal effect shortly.
Rubin-Neyman Causal Model. X has a causal effect on Y if (i) X happens earlier
than Y and (ii) if X had not happened, Y would be different [70].
Our study design ensures that the intervention X precedes the outcome Y , but
fulfilling the second conditions requires that we estimate the outcome for the same
patient both under intervention and without intervention.
Potential Outcomes. Every patient in the dataset has two potential outcomes: Y0
denotes their outcome had they not had the intervention X; and Y1 denotes the outcome
had they had the intervention. Typically, only one of the two potential outcomes can
be observed. The observable outcome is the actual outcome (denoted by Y ) and the
unobservable potential outcome is called the counterfactual outcome.
Using the definition of counterfactual outcome, we can now define the metric for
estimating the change in Y caused by X. Average Treatment response on the
Treated (ATT) [72] is a widely known metric in the causal literature and is computed as
follows: (X Y—S) = [Y1−Y0]X=1 = [Y1]X=1− [Y0]X=1, where denotes the expectation
and the X = 1 in the subscript signals that we only evaluate the expectation in the
treated patients (X = 1).
As we mentioned before, computing ATT for a large set X of interventions may
be difficult or even impossible because of the difficulty of finding comparable patients.
Thus we introduce the concept of differential causal effect, denoted by ∆ATT, which
quantifies the excess ATT that a new intervention x exerts on top of the set X ′ of
interventions the patient already receives:
(xY |S) = [Y1 − Y0]S,X′x=1.
[η - closed intervention set] An intervention set X is η-closed iff
∀x ∈ X, |ATT (xY |S,X\x)| > η.
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Intuitively, an intervention set X is η-closed if removing any intervention x reduces its
effect by at least η. In practical terms we would only add drug x to a cocktail X ′ if the
resultant cocktail X ′x is more effective than all of its subsets by at least η.
Biases. Beside X, numerous other variables can also exert influence over Y , leading
to biases in the estimates. The quintessential tool for eliminating or reducing these
biases is the causal graph, depicted in Figure 6.3. The nodes of this graph are sets of
variables that play a causal role and edges are causal effects. This is not a correlation
graph (or dependence graph), because for example, U and Z are dependent given X,
yet there is no edge between them.
Variables (items in I) can exert influence on the effect of X on Y in three ways:
they may only influence X, they may only influence Y or them may influence both X
and Y . Accordingly, variables can be put into four categories:
V are variables that directly influence Y and thus have
direct effect on Y
U are variables that only influence Y through X and
thus have indirect effect on Y ;
Z are variables that influence both X and Y and are
called confounders; and finally
O are variables that do not influence either X or Y
and hence can be safely ignored.
Figure 6.3: Rubin-Neyman Causal Model
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Much of the causal inference literature assumes that the causal graph is known and
true. In other words, we know apriori which variables fall into each of the categories,
U , Z, V and O. In our case, only X and Y are specified and we have to infer which
category each other variable (item) belongs to. Since this inference relies on association
(dependence) rather than causation, the discovered graph may have errors resulting in
misclassifications of variables into the wrong category. For example, because of the
marginal dependence between U and Y , variables in U can easily get misclassified as
Z. Such misclassifications do not necessarily lead to biases, but they can cause loss of
efficiency.
Problem Formulation. Given a data set D, a set S of subpopulation-defining
items, a set X of intervention items, a minimal support threshold θ and a minimum
differential causal effect threshold η, we wish to find all subpopulations S (S ⊂ S) and
all intervetions X (X ⊂ X ), X and S are disjoint, such that the causal rule XY |S is
frequent, namely it has support ((XY S) > θ) and its intervention set X is η-closed.
Causation has received substantial research interest in many areas. In computer
science, Pearl [73] and Rosenbaum[74] laid the foundation for causal inference. How-
ever, several fields such as cognitive science, econometrics, epidemiology, philosophy and
statistics have built their respective methodologies [75, 76, 77].
At the center of causation is a causal model. Arguably, one of the earliest and
popular models is the Rubin-Neyman causal model [70]. Under this model X causes
Y , if X occusr before Y ; and without X, Y would be different. Beside the Rubin-
Neyman model (counterfactual analysis), there are several other causal models, such
as Structural Equation Modeling [76], graphical models (causal graphical models [78]),
and the symbiosis between counterfactual and graphical models. In our work, we use
the potential outcomes framework from the Rubin-Neyman model and we use causal
graphical models to identify and correct for biases.
Causal graphical models are tools to visualize causal relationships among variables.
Nodes of the causal graph are variables and edges are causal relationships. Most methods
assume that the causal graph structure is a priori given, however, methods have been
proposed for discovering the structure of the causal graph [79, 80]. In our work, the
structure is partially given: we know the relationships among groups of variables, but
we have to assign each variable to the correct group based on data.
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Knowing the correct graph structure is important, because substructures in the
graph are suggestive of sources of bias. To correct for biases, we are looking for specific
substructures. For example, causal chains can be sources of overcorrection bias and
”V”-shaped structures can be indicative of confounding or endogenous selection bias
[77]. Many other interesting substructures have been studied [81, 82, 83]. In our work,
we consider three fundamental such structures: direct causal effect, indirect causal effect
and confounding. Of these, confounding is the most severe and has received the most
research interest.
Numerous methods exist to handle confounding, which includes propensity score
matching (PSM) [67], structural marginal models [77] and g-estimation [76]. The latter
two being specifically used for time-varying interventions [77].
Propensity score matching is used to estimate the effect of an intervention on an
outcome. The propensity score is the propensity (probability) of a patient receiving
the intervention given his baseline characteristics and the propensity score is used to
create a new population that is free of confounding. Many PSM techniques exist and
they typically differ in how they use the propensity score to create this new population
[84, 85].
Applications of causal modeling are not exclusive to social and life sciences. In data
mining, Lambert et al. [86] investigated the causal effect of new features on click through
rates and Chan et al. [87] used doubly robust estimation techniques to determine the
efficacy of display advertisements. Causal Modeling techniques have also been widely
utilized in EHRs [88] . In particular, Prunelli et al.[8] used PSM based techniques to
estimate the effect of 3-hour bundle sepsis guidelines on patient mortality and associated
complications.
Even extending association rules mining to causal rule mining has been attempted
before [89, 90, 91]. Li et al. [89] used the odds ratio to identify causal patterns and later
extended their technique [91] to handle large data set. Their technique, however, is not
rooted in a causal model and hence offers no protection against computing systematically
biased estimates. In their proposed causal decision trees [92], they used the potential
outcomes framework, but still have not addressed correction for various biases, including
confounding.
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6.4 Methods
6.4.1 Pruning Metrics
We can now present our algorithm for causal pattern mining. At a very high level, the
algorithm comprises of two nested frequent pattern enumeration [93] loops. The outer
loop enumerates subpopulation-defining itemsets S using items in S, while the inner
loop enumerates intervention combinations using items in X \S. More generally, X and
S can overlap but we do not consider that in this chapter. Effective algorithms to this
end exists [94, 95], we simply use Apriori [69].
Once the patterns are discovered, the ∆ ATT of the interventions are computed,
using one of the methods from Section 6.4.2 and the frequent, effective patterns are
returned.
On the surface, this approach appears very expensive, however several novel, ex-
tremely effective pruning strategies are possible and we describe them below.
Potential Outcomes Support Pruning. Let X be an intervention k-itemset, S be
a subpopulation-defining itemset, and let X and S be disjoint. Further, X−i be an
itemset that evaluates to ‘true’ iff all items except the ith item are ‘true’ but the ith
item is ‘false’. Using association rule mining terminology, all items in X except the ith
item are present in the transaction.
[Potential Outcomes Support Pruning] We only need to consider itemsets X such
that
min{(S,X), ({S,X−1), . . . ,
(S,X−k)} > θ.
In order to be able to estimate the effect of x ∈ X in the subpopulation S, we need
to have observations with x ‘true’ and also with x ‘false’ in S.
Potential Outcome Support Pruning is anti-monotonic.
Proof: Consider a causal rule XY |S . If the causal rule XY |S is infrequent, then
(XS) < θ ∨ ∃i, (X−iS) < θ.
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If (X−iS) had insufficient support, then any extension of it with an intervention item
x will continue to have insufficient support, thus the XxY |S rule will have insufficient
support. Likewise, if (XS) had insufficient support, then any extension of it with an
intervention item x will also have insufficient support.
Pruning based on Differential Causal Effect. Pruning based on differential causal
effect eliminates an intervention set X such that ∀x ∈ X, |ATT (xY |S,X\x)| ≤ η. In other
words, we eliminate the drug x from the cocktail that does not increase its causal effect
by at least η. While this pruning is not anti-monotonic, it is effective and produces
the most clinically relevant patterns. Consider interventions a,b and an intervention
set X, it is possible that ∆ATT (aY |X) < η and ∆ATT (bY |Xa) > η in which case we
incorrectly prune Xab. However, b is likely contributing much more to the effect of Xab
than a, thus the drug Xb likely captures most of the beneficial effect of Xab.
6.4.2 Causal Estimation Methods
∆ATT, our metric of interest, with respect to a single intervention x in a subpopulation
S is defined as
(xY |S) = [Y1 − Y0]S,Xx=1 ,
which is the expected difference between the potential outcome under treatment Y1 and
the potential outcome without treatment Y0 in patients with S who actually received
treatment. Since we consider treated patients, the potential outcome Y1 can be observed,
the potential outcome Y0 cannot. Thus at least one of the two must be estimated. The
methods we present below differ in which potential outcome they estimate and how they
estimate it.
For the discussion below, we consider the variables X, Z, U and V from the causal
graph in Figure 6.3. X is a single intervention, U , V and Z can be sets of items. For re-
gression models, we will denote the matrices defined by U , V and Z in the subpopulation
S as U , V and Z (same letter as the variable sets).
Counterfactual Confidence (CC). This is the simplest method. We simply assume
that the patients who receive intervention X = 1 and those who do not X = 0, do not
differ in any important respect that would influence Y . Under this assumption, Y1 in
the treated is simply the actual outcome in the treated and the potential outcome Y0 is
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simply the actual outcome in the non-treated (X = 0). Thus
= ((X = 1)Y |S)− ((X = 0)Y |S),
= (Y |S,X = 1)− (Y |S,X = 0)
In the followings, to improve readability, we drop the S subscript. All evaluations
take place in the S subpopulations.
Direct Adjustment (DA). We cannot estimate Y0 in the treated (X = 1) as the
actual outcome Y in the untreated, because the treated and untreated populations can
significantly differ in variables such as Z and V that influence Y . In Direct Adjustment,
we attempt to directly remove the effect of V and Z by including them in a regression
model. Since a regression model relates the means of the predictors with the mean of
the outcome, we can remove the effect of V and Z by making their means 0.
Let R be a generalized linear regression model, predicting Y via a link function g
g(Y |V,Z,X) = β0 + βV V + βZZ + βXX.
Then the (link-transformed) potential outcome under treatment is g(Y1) = β0 + βV V +
βZZ + βX and the potential outcome without treatment is g(Y0) = β0 + βV V + βZZ.
The ATT is then
=
[
g−1(Y1|V,Z,X = 1)
]
X=1
−[
g−1(Y0|V,Z,X = 0)
]
X=1
.
where g−1(Y1|V,Z,X = 1) is prediction for an observation with the observed V and
Z but with X set to 1. The (·)X=1 notation signifies that these expectation of the
predictions are taken only over patients who actually received the treatment.
The advantage of DA (over CC) is manyfold. First, it can adjust for Z and V as long
the model specification is correct, namely the interaction terms that may exist among
Z and V are specified correctly. Second, we get correct estimates even if we ignore
U , because U is conditionally independent of Y given X. This unfortunately only is a
theoretical advantage, because we have to infer from the data whether a variable is a
predictor of Y and U is marginally dependent on Y , so we will likely adjust for U , even
if we don’t need to.
75
Counterfactual Model (CM). In this technique, we build an explicit model for the
potential outcome without treatment Y0 using patients with X = 0. Specifically, we
build a model g(Y—V,Z,X=0)=β0 + βV V + βZZ. and estimate the potential outcome
as g(Y0|V,Z) = g(Y |V,Z,X = 0). The differential causal effect is then = (Y—X=1) -[
g−1(Y0|V,Z)
]
X=1
.
Similarly to Direct Adjustment, the Counterfactual Model does not depend on U .
However, in case of the Counterfactual Model, we are only considering the population
with X = 0. In this population, U and Y are independent, thus we will not include U
variables into the model.
Propensity Score Matching (PSM). The central idea of Propensity Score Matching
is to create a new population, such that patients in this new population are compara-
ble in all relevant respects and thus the expectation of the potential outcome in the
untreated equals the expectation of the actual outcome in the untreated.
Patients are matched based on their propensity of receiving treatment. This propen-
sity is computed as a logistic regression model with treatment as the dependent variable
log odd(X) = β0 + βV V + βZZ.
Patient pairs are formed, such that in each pair, one patient received treatment and the
other did not and their propensities for treatment differ by no more than a user-defined
caliper difference ρ.
The matched population has an equal number of treated and untreated patients, is
balanced on V and Z, and thus the patients are comparable in terms of their baseline
risk of Y . Hopefully, the only factor causing a difference in outcome is the treatment.
For estimating , the potential outcome without treatment is estimated from the ac-
tual outcomes of the patients in the matched population who did not receive treatment:
= [Y1 − Y0]
= (Y |X = 1,M)− (Y |X = 0,M),
where M denotes the matched population.
Among the methods we consider, propensity score matching most strictly enforces
the patient comparability criterion, however, it is susceptible to misspecification of the
propensity regression model, which can erode the quality of the matching.
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Stratified Non-Parametric (SN). In the stratified estimation, we directly compute
the expectation via stratification. The assumption is that the patients in each stratum
are comparable in all relevant respects and only differ in the presence or absence of
intervention. In each stratum, we can estimate the potential outcome Y0 in the treated
as the actual outcome Y in the untreated.
= [Y1 − Y0]X=1
=
∑
l
P (l|X = 1) [P (Y1|l,X = 1)− P (Y0|l,X = 1)]
=
∑
l
P (l|X = 1) [P (Y |l,X = 1)− P (Y |l,X = 0)] ,
where l iterates over the combined levels of V and Z. If we can identify the items that
fall into U , then we can ignore them, otherwise, we should include them as well into the
stratification.
The stratified method makes very few assumptions and should arrive at the correct
estimate as long as each of the strata are sufficiently large. The key disadvantage of
the stratified method lies in stratification itself: when the number of items across which
we need to stratify is too large, we may end up dividing the population into excessively
many small subpopulations (strata) and become unable to estimate the causal effect in
many of them thus introducing bias into the estimate.
6.5 Data and Study Design
In this study we utilized a large cohort of Mayo Clinic patients with data between 1999
and 2010. We included all adult patients (69,747) with research consent. The baseline of
our study was set at Jan. 1, 2005. We collected lab results, medications, vital signs and
status, and medication orders during a 6-year retrospective period between 1999 and the
baseline to ascertain the patient’s baseline comorbidities. From this cohort, we excluded
all patients with a diagnosis of diabetes before the baseline (478 patients), missing fasting
plasma glucose measurements (14,559 patients), patients whose lipid health could not
be determined (1,023 patients) and patients with unknown hypertension status (498
patients). Our final study cohort consists of 52,139 patients who were followed until the
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summer of 2010.
Patients were phenotyped during the retrospective period. Comorbidities of interest
include Impaired Fasting Glucose (IFG), abdominal obesity, Hypertension (HTN; high
blood pressure) and hyperlipidemia (HLP; high cholesterol). For each comorbidity, the
phenotyping algorithm classified patients into three broad levels of severity: normal,
mild and severe. Normal patients show no sign of disease; mild patients are either
untreated and out of control or are controlled using first-line therapy; severe patients
require more aggressive therapy. IFG is categorized into normal and pre-diabetic, the
latter indicating impaired fasting plasma glucose levels but not meeting the diabetes
criteria yet. For this study, progression to T2DM within 5 years from baseline (i.e. Jan
1, 2005) was chosen as our outcome of interest. Out of 52,139 patients 3627 patients
progressed to T2DM , 41028 patients did not progress to T2DM and the remaining
patients (7484) dropped out of the study.
6.6 Results
In this section, we present three evaluations of the proposed methodology. The first
evaluation demonstrates the computational efficiency of our pruning methodologies,
isolating the effect of each pruning methods: (i) Apriori support-based pruning, (ii)
Potential Outcome Support Pruning, and (iii) Potential Outcome Support Pruning in
conjunction with Effective Causal Rule Pruning. In the second section, we provide
a qualitative evaluation, looking at patterns involving statin. We attempt to use the
extracted patterns to explain the controversial findings that exist in the literature re-
garding the effect of statin on diabetes. Finally, in order to compare the treatment
effect estimates to a ground truth, which does not exits for real drugs, we simulate a
data set using proportions we derived from the Mayo Clinic data set.
6.6.1 Pruning Efficiency
In our work, we proposed two new pruning methods. First, we have the Potential
Outcome Support Pruning, which aims to eliminate patterns for which the ATT is not
estimable. Second, we have the Effective Causal Rule Pruning, where we eliminate
patterns that do not improve treatment effectiveness relative to the sub-itemsets.
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In Figure 6.4 we present the number of patterns discovered using (i) the traditional
Apriori support based pruning, (ii) our proposed Potential Outcome Support Pruning
(POSP), and (iii) POSP in conjunction with Effective Causal Rule Pruning (ECRP).
In Figure 6.4, the x-axis represents the minimum support threshold parameter(θ) and
the y-axis represents the number of patterns generated.
Figure 6.4: Comparison of Pruning Techniques
Apiori support based pruning only eliminates patterns based on support threshold.
POSP eliminates patterns for which the differential causal effect is not estimable due
to low sample size. POSP in conjunction with ECRP eliminates patterns for which the
differential causal effect is not estimable or the estimated is below the chosen threshold.
In other words, it eliminates patterns where the treatment is simply ineffective and thus
has low clinical relevance.
6.6.2 Statin
In this section, we demonstrate that the proposed causal rule mining methodology can
be used to discover non-trivial patterns from the above diabetes data set.
In recent years, the use of statins, a class of cholesterol-lowering agents, have been
prescribed increasingly. High cholesterol (hyperlipidemia) is linked to cardio-vascular
mortality and the efficacy of statins in reducing cardio-vascular mortality is well doc-
umented. However, as evidenced by a 2013 BMJ editorial [71] devoted to this topic,
statins are surrounded in controversy. In patients with normal blood sugar levels (la-
beled as NormalFG), statins have a detrimental effect, they increase the risk of diabetes;
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yet in pre-diabetic patients (PreDM), it appears to have no effect. What we demonstrate
below is that this phenomenon is simply disease heterogeneity.
First, we describe how this problem maps to the causal rule mining problem. Our set
of interventions (X ) consists of statin and our subpopulation defining variables consist
of the various levels of HTN, HLP and IFG (S). Our interest is the effect of statin (x)
on T2DM (Y ) in all possible subpopulations S, S ⊂ S.
In this setup, HLD, which is associated with statin use (statins treat HLD) and
T2DM, is a confounder (Z). A cholesterol drug, other than statin, (say) fibrates, are in
the U category: they are predictive of statin (patients on monotherapy who take fibrates
do not take statins), but have no effect on Y , because its effect is already incorporated
into the hyperlipidemia severity variables that defined the subpopulation. Variables that
only influence diabetes but not statin use (say HTN) would fall into the V category.
All subpopulations have variables that fall into Z and U and some subpopulation may
also have V .
The HLP variable uses statin as part of its definition, thus we constructed two new
variables. The first one is HLP1, a variable at the borderline between HLP-Normal and
HLP-Mild, consisting of untreated patients with mildly abnormal lab results (these fall
into HLP-Normal) and patients who are diagnosed and receive a first-line treatment
(they fall into HLP-Mild). Comparability is the central concept of estimating causal
effects and these patients are comparable at baseline. Similarly, we also created another
variable, HLP2, which is at the border of HLP-Mild and HLP-Severe, again consisting
of patients who are comparable in relevant aspects of their health at baseline.
S CC DA CM PSM SN
PreDM 0.145 0.022 0.010 0.022 0.017
NormFG 0.060 0.023 0.034 0.017 0.029
HLP1 0.078 0.019 0.014 0.010 0.010
HLP2 0.021 -0.013 -0.010 -0.021 -0.015
PreDM,HLP1 0.067 0.018 0.021 0.004 0.002
PreDM,HLP2 0.001 -0.038 -0.031 -0.048 -0.043
NormFG,HLP1 0.043 0.020 0.015 0.014 0.013
NormFG,HLP2 0.017 -0.002 -0.002 -0.005 -0.004
Table 6.1: ATT due to statin in various subpopulations S as estimated by the 5 proposed
methods.
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Table 6.1 presents the ATT estimates obtained by the various methods proposed in
Section 3.4 for some of the most relevant subpopulations. In this case, the intervention
set X consists of a single intervention, statin, thus reduces to the usual definition of
ATT. Negative ATT indicates beneficial effect and positive ATT indicates detrimental
effect.
Counterfactual confidence (CC) estimates statin to be detrimental in all subpop-
ulations. While statins are known to have detrimental effect in patients with normal
glucose levels [71], it is unlikely that statins are universally detrimental, even in patients
with severe hyperlipidemia, the very disease it is supposed to treat.
The results between DA, CM, PSM and SN are similar, with PSM and SN having
larger effect sizes in general. The picture that emerges from these results is that patients
with severe hyperlipidemia appear to benefit from statin treatment even in terms of their
diabetes outcomes, while statin treatment is moderately detrimental for patients with
mild hyperlipidemia.
Bootstrap estimation was used to compute the statistical significance of these re-
sults. For brevity, we report the results only for PSM. The estimates are significant
in the following subpopulations: NormFG, PreDM+HLP2 (p-values are ¡.001) and
NormFG+HLP1 (p-value .05).
The true ATT in these subpopulations is not know. To investigate the accuracy
that the various methods achieve, we use simulated data set that is largely based on
this example [71, 96].
6.6.3 Synthetic Data
In this section, we describe four experiments utilizing synthetic data sets, each of which
introduces a new potential source of bias. Our objective is to illustrate the ability of
the five methods from Section 6 for adjusting for these biases. We compare their ATT
estimates to the true ATT we used to generate the data set and discuss reasons for their
success or failure.
The rows of Table 6.2 correspond to the synthetic data sets in increasing order of the
biases we introduced and the columns corresponds to the methods: Conf (confidence),
CC (Counterfactual Confidence), DA (Direct Adjustment), CM (Counterfactual Model),
PSM (Propensity Score Matching) and SNP (Stratified Non-Parametric).
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Some of these methods, DA, CM, PSM and SNP take the causal graph structure into
account while estimating ATT. Specifically, they require the information whether a
variable is a confounder (Z), has a direct effect (V ), an indirect effect (V ), or no effect
(O).
In all of the data sets, we use a notation consistent with Figure 1: Z is the central
disease with outcome Y ; X is the intervention of interest that treats Z; V is another
disease with direct causal effect on Y , but V is independent of X; and U is a third
disease, which can be treated with X, but has no impact on Y . All data sets contain
5000 observations. When X is a single intervention, we use ATT and interchangeably.
I. Direct Causal Effect from V . We assume that every patient in the cohort has
disease Z at the same severity. They are all comparable w.r.t. Z. 30% of the patients
are subject to the intervention X aimed at treating Z, while others are not. Untreated
patients face a 25% chance of having Y , while treated patients only have 10% chance.
Some patients, 20% of the population, also have disease V , which directly affects Y : it
increases the probability of Y by 5%.
In this example the true ATT is -.15, as X reduces the chance of Y by 15%. Our
causal graph dictates that X and V be marginally independent, hence this this effect
is homogeneous across the levels of V . (Otherwise V would become predictive of X
and it would become a confounder. Confounding is discussed in experiments III-V.) All
methods estimated the ATT correctly, because ATT does not depend on V . We can
demonstrate this by stratifying on V and using the marginal independence of X and V .
= [(Y |X = 1)− (Y |X = 0)]
=
∑
v∈V
(V = v) [(Y |V = v,X = 1)− (Y |V = v,X = 0)]
=
∑
v∈V
[(Y, V = v|X = 1)− (Y, V = v|X = 0)]
= (Y |X = 1)− (Y |X = 0)
where v denotes the levels of V .
II. Indirect Causal Effect. The setup for this experiment is the same as for the
’Direct Causal Effect’ experiment, except we have disease U instead of V . Just like Z,
disease U is also treated by X, but U has no direct effect on Y ; its effect is indirect
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through X. U is thus independent of Y given X. The true ATT continues to be -.15.
Again, the ATT does not depend on U , hence all methods estimated it correctly. To
demonstrate that ATT does not depend on U , we use stratification and the conditional
independence of Y and U .
= [(Y |X = 1)− (Y |X = 0)]
=
∑
u∈U
[(Y |U = u,X = 1)(U = u|X = 1)
−(Y |U = u,X = 0)(U = u|X = 0)]
=
∑
u∈U
[(Y |X = 1)(U = u|X = 1)
−(Y |X = 0)(U = u|X = 0)]
= (Y |X = 1)
∑
u
(U = u|X = 1)−
(Y |X = 0)
∑
u
(U = u|X = 0)
= (Y |X = 1)− (Y |X = 0)
III. Confounding. In this experiment, we consider the simplest case of confounding,
involving a single disease Z, a single treatment X and outcome Y . 20% of the patients
have disease Z and 95% of the diseased patients are treated with X, while 5% are not.
All treated patients have Z. 25% of the untreated patients (Z = 1 and X = 0) have
outcome Y ; 10% of the treated patients (Z = 1 and X = 1) have the outcome; and only
5% of the healthy patients (Z = 0) have it. The true ATT is -.15.
In the presence of confounding, the counterfactual confidence and ATT do not coincide.
With z denoting the levels of Z and (z) being a shorthand for (Z = z),
= [(Y |X = 1)− (Y |X = 0)]
=
∑
z
(z) [(Y |X = 1, z)− (Y |X = 0, z)] ,
while the counterfactual confidence (CC) is
CC = (Y |X = 1)− (Y |X = 0)
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=
∑
z
[(Y |X = 1, z)(z|X = 1)
−(Y |X = 0, z)(z|X = 0)] .
When (z|X) 6= (z), these quantities do not coincide. However, any method that can
estimate (Y |X,Z) for all levels of Z and X will arrive at the correct ATT estimate. We
used logistic regression in our implementation of the Direct Adjustment method, which
can estimate (Y |X,Z) when X and Z have no interactions. Note that the causal graph
admits interaction between X and Z, thus model misspecification can cause biases in
the estimate.
IV. Confounding with Indirect Effect. In addition to the Confounding experiment,
we also have an indirect causal effect from U . We now have two diseases, Z and U , each
of which can be treated with X. 20% of the population has Z and independently, 20%
has U . 25% of the patients who have Z and have no treatment (X = 0) have Y , while
only 10% of the treated (X = 1) patients have it, regardless of whether the patient has
U . (If the probability of Y was affected by U , it would be another confounder, rather
than have an indirect effect.)
X has a beneficial ATT of -.15 in patients with Z == 1 (and X == 1) and has no effect
in patients with Z = 0 (who get X because of U). Thus the true ATT=-.0833.
In this experiment, the counterfactual model was the best-performing model. The
counterfactual model estimates the ATT through the definition
= [(Y1|X = 1)− (Y0|X = 1)] ,
where Y0 is the potential outcome the patient would have without treatment X = 0 and
(Y0|X = 1) is the counterfactual probability of Y (the probability of Y had they not
received X) in the population who actually got X = 1. Note that the potential outcome
Y1|X = 1 in the patients who actually got X = 1 is the observed outcome Y |X = 1.
With u and z denoting the levels of U and Z, respectively and (u) being a shorthand
for (U = u),
= [(Y |X = 1)− (Y0|X = 1)]
=
∑
u
∑
z
(u, z) [(Y |X = 1, u, z)− (Y0|X = 1, u, z)]
=
∑
z
(z)
∑
[(Y |X = 1, z)− (Y0|X = 1, z)]
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=
∑
z
(z)
∑
[(Y |X = 1, z)− (Y |X = 0, z)] ,
which coincides with the data generation mechanism, hence the estimate is correct.
In the derivation, step 2 holds because U and Z are independent given X and step
3 uses the fact that the counterfactual model estimates P0(Y |X = 1, z, u) from the
untreated patients, thus
(Y0|X = 1, z, u) = (Y |X = 0, z, u) = (Y |X = 0, z).
V. Confounding with Direct and Indirect Effects. In this experiment, we have three
diseases: our index disease Z, which is a confounder; U having an indirect effect on Y
via X; and V having a direct effect on Y . 20% of the population has each of Z, V
and U independently. 95% of patients with Z or U get the intervention X. 25% of the
untreated patients with Z get Y , while only 10% of the treated patients do, regardless
of whether they have U . Patients with V face a 5% in their chance of experiencing
outcome Y .
X has a beneficial ATT of -.15 in patients with Z = 1 and have no effect in patients
with Z = 0 (who get X because of U). Whether a patient has V does not influence the
effect of X. The true ATT is thus -.0833.
None of the methods estimated the effect correctly, but Propensity Score Matching
came closest. Analytic derivation of why it performed well is outside the scope of
this thesis, but in essence, its success is driven by its ability to maximally exploit
the independence relationships encoded in the causal graph. It can ignore V when it
constructs the propensity score model, because X and V are independent (when Y not
given); and it can ignore U and V when it computes the ATT in the propensity matched
population. On the other hand, the causal graph admits interaction among U , Z and
X, thus a logistic regression model as the propensity score model can be subject to
model misspecification.
The Stratified Non-Parametric method, which is essentially just a direct implementation
of the definition of ATT, underestimated the ATT by almost 25%. The reason lies in the
excessive stratification across all combinations of the levels of U , V , and Z. Even with
just three variables, most strata did not have sufficiently many patients (either treated
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or untreated) to estimate (Y |X,u, v, z). In the discussion, we will describe remedies to
overcome this problem.
Conf CC DA CM PSM SN
I. +.110 -.150 -.150 -.150 NA -.150
II. +.099 -.150 -.150 -.150 -.151 -.149
III. +.099 +.047 -.136 -.136 -.136 -.136
IV. +.077 +.024 -.019 -.083 -.068 -.064
V. +.072 +.038 -.037 -.105 -.074 -.067
Table 6.2: The ATT estimates by the 6 methods in the five experiments.
6.7 Discussion
In this section, we proposed the causal rule mining framework, which transitions pattern
mining from finding patterns that are associated with an outcome towards patterns that
cause changes in the outcome. Finding causal relationships instead of associations is
absolutely critical in health care, but also has appeal beyond health care.
The numerous biases that arise in establishing causation make quantifying causal
effects difficult. We use the Neyman-Rubin causal model to define causation and use
the potential outcome framework to estimate the causal effects. We correct for three
kinds of potential biases: those stemming from direct causal effect, indirect causal effect
and confounding. We compared five different methods for estimating the causal effect,
evaluated them on real and synthetic data and found that three of these methods gave
very similar results.
We have demonstrated on real clinical data that our proposed method can effectively
enumerate causal patterns in a large combinatorial search space due to the two new
pruning methods we developed for this work. We also demonstrated that the patterns
discovered from the data were very rich and we managed to illustrate how the effect of
statin is different in various subpopulations. The results we found are consistent with
the literature but go beyond what is already known about statin’s effect on the risk of
diabetes.
The discussions and experimental results provided in this chapter provide some
general guidance on when to use the different methods we described. We recommend
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counterfactual confidence if no confounding is suspected as counterfactual confidence
is computationally efficient and can arrive at the correct solution even when direct ef-
fects and indirect effects are present. In the presence of confounding, propensity score
matching gave the most accurate results, but due to the need to create a matched popu-
lation, it has built-in randomness, increasing its variance. Moreover, the counterfactual
model as well as the propensity score model are susceptible to model misspecification. If
unknown interactions among variables are suspected, we recommend the stratified non-
parametric method. With this technique, model misspecification is virtually impossible,
however, its sample size requirement is high. The stratified model is suboptimal if we
need to stratify across many variables. Stratifying across many variables can fragment
the population into many strata too small to afford us with the ability to estimate the
effects correctly. If the estimates use some strata but not others, they may be biased.
Chapter 7
Conclusion and Future Work
In this thesis we aim to extract insightful information from Electronic Health Records
(EHRs). In particular, we proposed techniques to model irregular time-series datasets
from EHR. Further, we also proposed techniques which can be used to estimate the
effect of medical and surgical interventions. To summarize, In Chapter 1 we present a
brief overview of the existing state of healthcare in U.S. and how the current state is
lacking behind other developed nations w.r.t several key statistics. We also provided a
discussion on how the HITECH and ACA acts aim to improve the current state of U.S.
healthcare. In chapter 2, we introduced EHRs and provided a brief discussion about
the kind of data elements which are stored in an EHR. We then discussed the various
challenges and opportunities associated with modeling EHRs.
In chapter 3, we introduced techniques which can be used to extract associative
patterns from EHRs in the absence of longitudinal data. We discussed our methodolo-
gies within the context of T2DM. In chapter 4, we presented novel methodologies to
extract associative patterns from EHRs in the presence of longitudinal data. Further,
we also discussed how events which occurred close to the outcome are more predictive
as compared to events which happened much earlier. In chapter 5, we presented tech-
niques which can be used to extract simple causal patterns. Patterns in which we aim
to estimate the effect of interventions on outcomes while only incorporating the effect
of confounders. In chapter 6, we presented techniques which can be used to estimate
complex causal patterns. Such patterns were extracted in the context of T2DM. In 7.1
we provide a brief summarization of the layout of our thesis.
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Figure 7.1: Thesis Discussion
7.1 Future Work
There are several directions in which this thesis can be extended in the future. In this
thesis we used domain knowledge to identify variables whether they are confounding
variables or exogenous variables. In future, more sophisticated techniques can be de-
veloped to automatically identify whether the variables are confounding, exogenous or
independent. Such techniques can be developed using partial association tests and other
similar statistical framework. Such automatic classification of variables will help us in
more accurate estimation of the causal effect of medical and surgical interventions on
various outcomes of interest.
Another interesting area for future research lies in the field of online causal estima-
tion. Currently, we perform oﬄine causal estimation i.e. any estimation of any medical
intervention on outcomes of interest is performed using the entire datasets. This is
not only time consuming but also a repetitive process as the whole analysis has to be
computed when a new data set arises. By online causal estimation we imply techniques
where in by using the new data to slightly tailor the existing model (computed using old
data). Such techniques can then have various associated opportunities. Such techniques
have the potential to create alarms when the new intervention estimates deviate from
the old estimates.
We also hope that the techniques developed in this thesis for diseases such as T2DM
and sepsis can also be applicable for other diseases. Further the techniques and results
obtained on our data cohorts should be verified using data cohorts across geographies.
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This would ensure the validity of our techniques as well as the validity of our mod-
els. Moreover, sophisticated techniques still need to be developed to handle challenges
associated with modeling EHRs such as censoring, irregular time-series and missing
data.
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